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SUMMARY 
 
Glioblastoma multiforme (GBM) is one of most common and still poorly treated primary 
brain tumors. This pathology represents a dramatic challenge for researchers and clinicians 
and the biology underlying this cancer is not yet fully elucidated. So far, the existence of a 
subpopulation of cancer stem cells, responsible for GBM growth and aggressiveness, has been 
extensively demonstrated. Thus, the possibility of reprogramming this subpopulation toward 
less aggressive phenotypes has been rapidly growing during years. To reach this aim, 
however, a more complete understanding of the mechanisms preserving Glioma Stem Cells 
(GSCs) phenotype is needed, in particular considering the role of the microenvironmental 
stimuli driving GBM cell proliferation and self-renewal. In this context, hypoxia has assumed 
a fundamental role as a key regulator of signaling pathways involved in GSCs proliferation 
and tumor progression. For this reason, the characterization of the hypoxic niche where GSCs 
reside revealed that hypoxia, through HIF-1α transcription factor, can regulate several 
biological processes which are exploited by different populations of cells in the tumor mass in 
order to survive. The Wnt/β-catenin/TCF cascade is one of the most important hypoxia-
modulated pathway implicated in tissue development and in the progression of several human 
cancers. Interestingly, our laboratory previously characterized a biological process that 
impacts on GSCs phenotype and that is regulated in synchrony by HIF-1α and the Wnt 
pathway. Indeed, in hypoxic conditions, Wnt pathway activation is able to induce a pro-
differentiating switch of GSCs toward neurons, weakening their aggressive phenotype. This 
process is strictly dependent from environmental oxygenation and can be exploited to 
reprogram GSCs and neutralize their resistance to treatments. Here, we deepen into the 
mechanisms underlying this pro-differentiating process in primary GBM-derived cells and, in 
particular, we aim to finely characterize the role of the Wnt pathway transcriptional effectors 
TCF1 and TCF4 in controlling GBM phenotype. Once observed that Wnt pathway activation 
was able to mediate two different phenotypic effects at different oxygen levels in GBM cells, 
we found that, in hypoxia, the observed neuronal differentiation process of GBM cells was 
mediated by a molecular complex formed by TCF1, HIF-1α and β-catenin. Moreover, ChIP-
sequencing experiments confirmed the capacity of the above mentioned complex to sit on 
promotorial sequences above the DNA and, in turn, trigger the expression of specific genes 
involved in the neuronal differentiation processes. As a confirmation, TCF1 knockdown in 
GBM cells cultured in hypoxia completely blocked the neuronal differentiation process. On 
the other hand, TCF4 expression resulted to be preponderant in normoxia, where we assumed 
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that TCF4E inhibitory isoforms could block this Wnt-dependent neuronal differentiation 
observed. Indeed, GBM cells cultured in normoxic conditions are characterized by an high 
expression of TCF4E which probably blocks the neuronal differentiation process mediated by 
TCF1 and HIF-1α. Moreover, in normoxic conditions ChIP-sequencing experiments 
suggested TCF4 as able to bind the same genomic regions controlled by the TCF1/HIF-1α 
molecular complex which assembles in hypoxic conditions. Further demonstrations for this 
hypothetical inhibitory function of TCF4 came from functional experiments in which we 
silenced TCF4 in normoxia. Herein, we observed an induction of the neuronal differentiation 
and a complete block of this process when GBM cells were forced to over-express the 
inhibitory isoforms TCF4E.  
 
Conclusions 
In this study we demonstrated that the cooperation between the Wnt pathway transcriptional 
co-factor TCF1 and HIF-1α is able to induce a long-lasting neuronal differentiation process in 
GBM cells. Indeed, Wnt pathway activation induces a switch from a stem-like phenotype 
towards neurons and triggers, exclusively under hypoxia, a TCF1/HIF-1α-dependent 
transcription of neuronal differentiation genes. This process is impaired upon standard oxygen 
conditions (20% O2) by the binding of TCF4 to the same genes on distal sequences, thus 
exerting an inhibitory function on this process. 
In conclusion, we unveil a tightly regulated mechanism by which the TCF1/HIF-1α 
transcriptional complex is able to induce a reminiscent neuronal differentiation of GSCs, 
which might represent a future potential strategy to therapeutically weaken their 
aggressiveness. 
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SOMMARIO 
 
Il Glioblastoma multiforme (GBM) è il più comune dei tumori cerebrali nell’adulto e 
rappresenta tuttora una patologia dalla prognosi molto infausta e senza trattamenti efficaci. 
Purtroppo i meccanismi biologici che portano alla formazione di questo tumore e che ne 
sostengono l’aggressività sono scarsamente caratterizzati. Finora molte evidenze scientifiche 
dimostrano come una piccola popolazione di cellule staminali tumori sia la responsabile 
dell’insorgenza e della crescita del GBM. Di conseguenza, la possibilità di riprogrammare 
queste cellule verso un fenotipo meno aggressivo e differenziato è stata valutata da molti 
ricercatori negli ultimi anni. Per capire in maniera più approfondita i meccanismi responsabili 
del mantenimento del fenotipo staminale di queste cellule diventa di fondamentale importanza 
studiare approfonditamente il microambiente circostante la massa tumore del GBM e 
caratterizzare gli stimoli che guidano la proliferazione e l’autorinnovamento delle cellule di 
GBM. Il microambiente tumore è costituito da un gradiente di ossigeno per cui le cellule 
tumori sfruttano bassi livelli di ossigeno, condizione denominata ipossia, per mantenere le 
loro caratteristiche staminali. Lo studio della nicchia ipossica in cui risiedono le cellule tumori 
di GBM ha portato alla dimostrazione che il fattore di trascrizione HIF-1α è responsabile del 
controllo di numerosi processi biologici responsabili del mantenimento del fenotipo 
scarsamente differenziato di queste cellule. Tra le molteplici vie di segnale regolate da HIF-1α 
troviamo il pathway di Wnt/β-catenin. Studiando le relazioni che intercorrono tra queste due 
vie di segnale, il nostro gruppo di ricerca ha caratterizzato un meccanismo biologico di 
differenziamento neuronale delle cellule di GBM indotto in sincronia dalle vie di segnale  
controllate da HIF-1α e Wnt. Questo processo risulta essere fortemente dipendente dai livelli 
di ossigeno presenti nel microambiente. Infatti, cellule di GBM coltivate in condizioni di 
ipossia vanno incontro a differenziamento neuronale dopo attivazione del pathway di Wnt. 
Tale processo potrebbe rappresentare uno strumento efficace per riprogrammare le cellule di 
GBM verso un fenotipo meno aggressivo e per questo motivo abbiamo approfondito i 
meccanismi che inducono tale processo nelle cellule primarie di GBM derivate da paziente. Il 
nostro obiettivo è stato quello di caratterizzare in maniera univoca il ruolo dei fattori 
trascrizionali TCF1 e TCF4, appartenenti alla via di segnale di Wnt, nel determinare il 
fenotipo del GBM. Abbiamo confermato che l’attivazione del pathway di Wnt induce due 
diversi effetti fenotipici nelle cellule di GBM a diverse concentrazioni di ossigeno. 
Successivamente abbiamo dimostrato che, in condizioni di ipossia, il differenziamento 
neuronale osservato nelle cellule di GBM è mediato da un complesso trascrizionale formato 
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da TCF1, HIF-1α e β-catenin. Inoltre, esperimenti di ChIP-sequencing hanno confermato la 
capacità di questo complesso trascrizionale di regolare in maniera attiva specifiche sequenze 
genomiche del DNA delle cellule di GBM ed attivare la trascrizione di geni implicati in 
processi di differenziamento neuronale. Abbiamo confermato questi risultati silenziando 
TCF1 nelle cellule di GBM coltivate in condizioni di ipossia ed abbiamo dimostrato che il 
differenziamento neuronale, altrimenti indotto in presenza di TCF1, viene completamente 
bloccato dopo attivazione del pathway di Wnt. Al contrario, abbiamo riscontrato una 
preponderante espressione di TCF4 ad alti livelli di ossigeno (ossigeno ambientale, 20%), in 
cui le cellule di GBM non subiscono il differenziamento neuronale osservato in ipossia e 
mantengono un fenotipo prettamente staminale. Per giustificare tale fenotipo dopo attivazione 
del pathway di Wnt,  abbiamo ipotizzato che, tra le molteplici isoforme di TCF4, quelle a 
carattere inibitorio sulla trascrizione potessero bloccare il processo di differenziamento 
neuronale, altrimenti attivato dal pathway di Wnt in ipossia, e favorire il fenotipo non 
differenziato delle cellule di GBM. Per dimostrare quest’ipotesi abbiamo silenziato TCF4 in 
cellule di GBM coltivate in normossia ed abbiamo osservato che l’attivazione del pathway di 
Wnt induce in maniera significativa il differenziamento neuronale osservato in ipossia. 
Inoltre, se le cellule di GBM sono forzate ad esprimere l’isoforma inibitoria di TCF4, TCF4E, 
il fenotipo acquisito dalle cellule di GBM risulta essere non differenziato, confermando la 
capacità di inibire tale processo in cellule di GBM coltivate ad alti livelli di ossigeno.  
 
Conclusioni 
In questo studio abbiamo dimostrato che la cooperazione tra il pathway di Wnt e HIF-1α  è in 
grado di indurre un cambiamento nel fenotipo di cellule di GBM in condizioni di ipossia. Il 
processo di differenziamento neuronale osservato in queste cellule dipende esclusivamente 
dal microambiente e, in particolare, risulta essere specifico per cellule non differenziate di 
GBM coltivate in ipossia. La dimostrazione che è possibile modulare il fenotipo di queste 
cellule in maniera specifica e dipendente dai livelli di ossigeno rappresenta una potenziale 
strategia futura per ridurre l’aggressività e la resistenza ai trattamenti di queste cellule.  
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INTRODUCTION 
 
Glioblastoma multiforme 
 
Brain tumors consist of a diverse group of neoplasms afflicting both children and adults and 
are among the human cancers with the poorest outcome (1). Glioblastoma multiforme (GBM) 
is a primary brain neoplasm, consisting of a genetically and phenotypically heterogeneous 
group of tumors. Ninety percent of GBM cases develop de novo (primary GBM) from normal 
glial cells by multistep tumorigenesis. The remaining 10% of gliomas are cases of secondary 
neoplasm, developing through progression from low-grade tumors (diffuse or anaplastic 
astrocytomas) (2). Although many risk factors associated the development of GBM have 
remained unidentified, risk factors such as exposure to ionizing radiation have proven to be 
detrimental for disease development in some cases. Other risk factors including cell phone 
use, head trauma, and pesticide exposure have yet to be confirmed as increasing risk for 
gliomagenesis. Symptoms of disease depend on the specific location of the tumor, and 
diagnosis is most commonly made following surgical resection. The prognosis for patients 
with GBM is often very poor (only 2% of patients aged 65 years or older, and only 30% of 
those under the age of 45 years at diagnosis, survive for 2 years or more), and treatments to 
cure this cancer have yet to be devised (3). 
GBM is characterized by highly proliferative and invasive capacities in order to infiltrate 
surrounding tissues as fast as possible and leading to dramatic aggressiveness and 
progression. As a consequence, the tumor mass is not clearly distinguishable from the normal 
tissue and, unfortunately, the complete resection of GBM tumor mass is almost impossible, 
with radiotherapy not always efficient. Moreover, the blood-brain barrier makes treatment 
more difficult. In addition, tumor cells found in the areas of hypoxia are resistant to 
radiotherapy. Surgical resection to the extent feasible, followed by chemotherapy and 
radiotherapy, is the mainstay of GBM treatment. Surgical treatment, chemotherapy and 
radiotherapy prolong the survival time in young people up to 202 weeks. However, even after 
the maximal safe surgical resection, GBM could easily relapse and the tumor often become 
more aggressive (2). Unfortunately, the establishment of a new tumor mass, which occurs in 
almost all patients, still decrease their short survival possibilities (4).  
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Neural stem cells (NSCs) and Cancer Stem Cells (CSCs) 
 
Treatment failure of GBM is in part due to a poor knowledge of the mechanisms regulating 
GBM tumor growth and aggressiveness and understanding these mechanisms is the major 
challenge that researchers have to face. The fundamental problems not yet resolved are which 
are the cells in the diverse tumor populations that initiate and maintain brain tumor growth 
and what are the molecular mechanisms involved in this phenomenon. In the adult brain, 
neural stem cells (NSCs) were observed at any stage of the development, from the embryo to 
the adult organism. NSCs are primarily located in the subventricular zone (SVZ) (5), in the 
subgranular zone (SGZ) and the dentate gyrus of the hippocampus (5). In particular, NSC 
have been described to reside in their specific niches around the blood vessels where they are 
in communication with other cells and the extracellular matrix. Different cellular types are 
present in these niches, such as neuroblasts and transitory amplifying progenitors, all 
surrounded by ependymal cells (6,7). NSCs are multipotent cells capable of multi-lineage 
differentiation as a result of which they lose their stem properties (8). NSCs divide 
symmetrically for self-renewal and generate differentiated progeny (neurons, astrocytes, 
oligodendrocytes) through asymmetric divisions (Figure 1A). Moreover, their proliferative 
capacity and the association with blood vessels stimulate NSCs to migrate and colonize 
surrounding tissues. While NSCs are necessary for a correct neurological development and 
activity, cells with aberrant NSC characteristics have been often correlated to brain tumors. 
Indeed, increasing evidences suggest the existence of a population of CSCs or tumor initiating 
cells (TICs) with high self-renewal ability, thus promoting brain tumor growth (9). In the light 
of the “CSC hypothesis”, the transformation of NSCs or progenitors into CSCs follows the 
rules of the normal physiology, but with aberrant order, timing and intensity of the underlying 
mechanisms sustaining the disruption of the regulatory mechanisms that control self-renewal 
and proliferation and contributing to the formation of an aberrant disorganized tissue (Figure 
1B). CSCs may originate from normal NSCs undergoing tumorigenic alterations. Differently, 
they can derive from more differentiated or terminally differentiated transit-amplifying neural 
cells being affected by multiple mutations, thus reverting to a stem phenotype. Moreover, an 
arrest of the normal maturation process of the NSC has been also reported, thus leading to 
intensive cell division and lack of differentiation. CSCs originating through these different 
processes are generally described as a small sub-population of dividing cells with stem cell-
like properties, huge self-renewal ability, peculiar genetic alterations, tumorigenic potential, 
and the ability to differentiate into all different bulk tumor cells (10). During last years, the 
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connection between normal stem cells and cancer has emerged in many tissues, particularly, 
blood, mammary gland, gut, skin and brain. Thus, researchers have proposed the so called 
“hierarchical model” of tumor progression in which malignant tumors are initiated and 
maintained by a population of tumor cells that share similar biologic properties with normal 
adult stem cells. This model, supported by increasing experimental data, holds that only a rare 
subset of cells within the tumor own unlimited proliferation capacity and, in particular, the 
ability to self renew and differentiate into the different cellular subtypes that form the mass. 
This hypothesis postulates that a population of cells with stem cell-like features (CSCs) exists 
in tumors and it is able to generate new tumors when transplanted. This cell population would 
be able to give rise to the whole cellular bulk of the tumor mass, with the remainder cells 
representing differentiating or terminally differentiated cells originated by a stem cell 
precursor that sits on top of the tumor’s “differentiation hierarchy”. Under certain conditions, 
non-CSCs can become CSCs and exhibit an enhanced ability to form spheres, thereby 
suggesting that the CSC state may be plastic (11). Several groups studying human brain 
tumors identified small numbers of cells with clonogenic potential based on the neurosphere 
assay. In culture, these brain tumor cells form self-renewing neurosphere-like colonies, and 
they have the ability to differentiate into one or more neural lineages. Moreover, a growing 
body of evidence indicate that these rare populations of brain cancer cells, termed GBM stem 
cells (GSCs), are characterized by the ability to generate xenografts representing the initial 
tumor in immunodeficient animals and to divide asymmetrically to allow self-renewal as well 
as differentiation into a non-CSC population (2). GSCs expressed both neuronal and astroglial 
markers on differentiation, together with several key determinants of neural stem cell fate, 
that can be often used for their identification. CD133 (also known as prominin-1) along with 
nestin, SOX2, Bmi1, Musashi, CD44, CD15, or ABC transporter proteins (11). Since GBM 
tumors display high degree of phenotypic, cellular, genetic, and epigenetic heterogeneity, it is 
plausible to believe that a major problem in the unresponsiveness of GBM tumors to therapy 
is the existence of GSCs within the tumor (12). Unfortunately, GSCs role during initiation, 
progression, and recurrence of GBM has been accepted to be the primarily responsible for 
radiation and chemotherapy resistance and poor survival of GBM patients (13).  
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Figure 1. Stem cell hierarchy in normal brain and brain tumours. 
(A) Normal brain: rare neural stem cells in the brain are able to self-renew to maintain themselves and also 
generate progenitors that proliferate and then differentiate into mature cells that form the highly organized brain 
parenchyma. (B) Brain tumors: cancer stem cells are dysregulated in terms of self renewal and proliferation and 
they aberrantly differentiate into cells that form the bulk of the disorganized cancer tissues (2). 
 
Tumor microenvironment and the hypoxic/vascular niches 
 
Microenvironment represents a fundamental mediator in maintaining the aggressive behavior 
of GSCs and an inexhaustible source of stimuli pushing tumor progression. Indeed, GBM 
complexity is driven by numerous stimuli which originate from the microenvironment, 
suggesting its importance also for its pathogenesis and the documented resistance to therapy. 
It has been described that GBMs display high cellular heterogeneity (9) described a model 
which integrates the plethora of signals which regulate GBM plasticity. GBM cells 
communicate with the perivascular niche and with the hypoxic niche, by originating a 
“teamwork”, withstanding to hierarchic rules and complex networks. The three-layers 
concentric model represents a clear explanation to elucidate the complexity of signals 
integration in GBMs, particularly deriving from microenvironment. According to the 
hierarchical theory for tumor progression, the “tumor-initiating cells” GSCs may originate 
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from the SVZ and the SGZ, which include progenitor cells able to originate multi-lineage 
differentiated cells. These specific niches are essential for maintaining stemness and self-
renewal properties of GBM precursors, which are secondly instructed to proliferate and 
differentiate. The central area of the tumor mass consists of a necrotic core, highly hypoxic 
and enriched in GSCs, and as going to the periphery, the tumor mass includes an intermediate 
layer, hypoxic and rich in GSCs too. The surrounding peri-tumor zone corresponds to the 
peripheral layer of the “three-layer model”, and it is highly vascularized and presents few 
GSCs and more differentiated cells. A hypoxic gradient is arranged from the core to the 
periphery, associated to a progressive change in the expression of specific markers, from 
CD133 and Nestin in the necrotic area, to differentiation markers, such as GFAP and β-III-
tubulin, in the more oxygenated periphery (Figure 2). 
 
 
Figure 2. The three layer model of glioblastoma. 
In this model GSCs are located along the hypoxic gradient in the tumor mass, mostly residing in the inner 
portions of the mass and in the so called perivascular niche. A hypoxic gradient is present from the tumor core to 
the periphery, associated to a progressive change in the expression of specific markers such as stemness markers, 
like CD133 and Nestin in the necrotic area, to differentiation markers, such as GFAP and β-III-tubulin, in the 
more oxygenated periphery (3). 
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Two main niches are detected in GBM microenvironment, the hypoxic and the peri-vascular 
ones. They finely regulate cellular fate by releasing numerous stimuli, which promote cell 
differentiation or stemness maintenance. GBMs are highly vascularized tumors, characterized 
by strong angiogenesis, but the blood flow is not the only key factor to play a pivotal role in 
contributing to the complexity of vascular microenvironment, since many cell types infiltrate 
the tumor mass. In particular, the peri-vascular niche consists of the surrounded area of 
angiogenic and tumor microvascular structures, characterized by the presence of several 
mature and differentiated cells (endothelial cells, fibroblasts, astrocytes, macrophages or 
microglia) which orchestrate intercellular crosstalk. Endothelial cells are the principal 
components of the vascular niche, and they differ from endothelial cells which constitute 
vessel walls. Blood flow is necessary to provide oxygen and nutrients to GBM cells, 
particularly to CSCs, nevertheless many non-structural endothelial cells exist, and they 
remain separate from tumor capillaries, without increasing the tumor microvascular density. 
They have the task of releasing a lot of diffusible factors to maintain the self-renewal ability 
of neural stem cells and neurogenesis. On the other hand, GBM cells release pro-angiogenic 
stimuli like VEGF to recruit endothelial cells which proliferate and give rise to new 
capillaries. Moreover, other pro-angiogenic mechanisms were described for GBM 
angiogenesis, such as the transdifferentiation of cancer stem cells into tumor-derived 
endothelial cells (TDECs), in order to continuously preserve the vascular microenvironment 
(14–16). Pericytes are contractile cells which are tightly associated to endothelial cells, 
endowed with the function of stabilizing and maintaining the integrity of the newly formed 
tumor vessels. They has been described to be involved in the regulation of the angio-
architecture structural shape of the tumor vascular niche, and they intimately depend on 
endothelial cells along the vessel walls. Analogously, astrocytes are closely associated to the 
endothelial cells forming blood vessels, and they both maintain the integrity of the blood 
brain barrier, and produce neurotrophic factors which promote GBM proliferation (17). 
Fibroblasts reside in the peri-vascular niche, and they are responsible of GBM invasion, as 
reported for other cancer types. They express critical markers associated to tumor progression 
and malignancy, such as metalloproteases (pro-MMP2). The presence of tumor induces a 
physiological immune response, and GSCs showed the expression of pro-inflammatory genes, 
which stimulate the enrichment of microglia at the tumor peri-vascular site. Microglia are the 
macrophages which lie in brain tissue, and they are the principal cytokine stimulators 
important for tumor proliferation, migration and progression. They are located in many sites, 
depending on their role. They promote metastasis when arranged in the perivascular space, 
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cell motility and invasion when sited in the advanced tip of tumor, and their localization in the 
peri-necrotic area increases angiogenesis, explaining the positive correlation between 
macrophages infiltration and vascular density in gliomas (18,19). The combination of all these 
cell types results in a complex system of crosstalk between cells, which culminates in a fine 
balance of a plethora stimuli for GBM cells. Particularly, GSCs are strictly connected to 
endothelial cells, as well as other stromal cells, defining the entirely plasticity, typical of the 
tumor microenvironment. It has been observed that GSCs arrange themselves along the 
capillaries, in order to be prone to respond to signaling cues deriving from endothelium, by 
direct cell-to-cell contact and soluble factors. They stimulate GSCs to proliferate and self-
renew, and the increase of the number of endothelial cells has been associated to an 
accelerated brain tumor initiation and growth. On the other hand, GSCs express elevated 
levels of VEGF or other pro-angiogenic factors, which in turn stimulate endothelial cells to 
proliferate and undergo angiogenesis. This evidence shows a bidirectional signaling and 
cross-talk between stem cells and vascular niche (16). A peculiar aspect of GBM 
microenvironment is the hypoxic niche. GBM mass is characterized by low oxygen 
concentrations, ranging between 0.1 % and 2.5 %, different from the healthy brain, which 
physiologically range between 12.5 % and 2.5 % of oxygen. GBMs are marked out by 
hypoxic gradients, which present areas with moderate or severe hypoxia, and necrotic zones 
in the tumor core. The inner layer shows a considerable expression of hypoxic markers, 
associated to tumor aggressiveness and GSCs maintenance (3). 
Studies conducted on GBM-derived cells confirmed the importance of oxygen tension in 
determining the phenotype of GBM cancer cells and that oxygen is a critical parameter in 
interpreting standard laboratory culture conditions (21% oxygen) versus the in 
vivo microenvironment, known to be hypoxic. Increasing oxygen tension promotes activation 
of the pro-apoptotic intracellular pathway in GBM-derived cells and the percentage of 
CD133
+
 GSCs decreased after acute exposure to environmental oxygen, with a corresponding 
increase in CD133
−
 cells enriched in GFAP
+
 astrocytes , consistent with a pro-differentiating 
effect. Additionally, normal brain precursors behaved in the same way, indicating that low 
oxygen tensions play a physiological protective role in maintaining the resident stem cells 
pool (11). 
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GBM resistance to treatments 
 
GBM display high resistance to conventional radiotherapy and chemotherapy (20). Indeed, 
soon after their initial description, GSC resistance to treatments have been described (21,22), 
thus suggesting them as one the principal contributors to GBM tumor recurrence. GSCs have 
been demonstrated to be more resistant to radiation than the non-stem glioma cells (21). 
Indeed, chemotherapy with Temozolomide (TMZ) delays GBM tumor growth, but long term 
survivors are extremely rare and recurrence after TMZ therapy strongly indicates the presence 
of TMZ-resistant GSCs (23). In an in vivo mouse model of GBM, TMZ treatment increased 
tumor side population (SP), a cell population that have been described to be enriched in 
CSCs, suggesting that TMZ treatment could even favor tumor recurrence (24). For these 
reasons, it is now widely accepted that GSCs contribute to GBM recurrence after 
conventional therapies. Initial models of GSC regulation have been based on neural stem cell 
(NSC) biology, the most similar cellular surrogate. In this context, GSCs seem to be governed 
by pathways which are already active during brain development, including Notch, Wnt, bone 
morphogenetic proteins (BMP), transforming growth factor-β (TGF-β ), other RTK pathways 
(3,25). 
 
HIF-1α pathway 
 
To better investigate the characteristics of the exclusive niche where GSCs reside, it is 
fundamental to study the mechanisms responsible of the low oxygen tension maintenance. A 
milestone in understanding oxygen physiology was the identification by Wang and Semenza 
of the HIF transcriptional complex, which is the key intracellular molecular system of the 
hypoxic response (26). In particular, activation of HIF-1α transcription factor is the most 
recognized pathway adopted by hypoxic cells to survive and maintain tumor progression. 
HIF-1α protein activity and accumulation are regulated at different levels through its life 
cycle inside the cells. Independently from O2 levels, HIF-1α is constitutively transcribed and 
synthesized through a series of signaling events involving several growth factors and other 
signaling molecules. Under normoxic conditions, HIF-1α protein expression is negatively 
regulated by proteosomal degradation and ubitiquination in a pathway involving von Hippel-
Lindau protein (VHL), a tumor suppressor, and one of the recognized components of an E3 
ubiquitin protein ligase. The two proline residues located in the LXXLAP amino acid motif in 
the Oxygen Dependent Degradation Domain (ODDD) of HIF-1α were found to be good 
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substrates for the action of a group of enzymes called proly1-4-hydroxylases (PHD 1,2,3). 
These are 2-OG-dependent dioxygenases enzymes which require oxygen for their 
hydroxylation action. Hence, hydroxylation of proline residues by PHDs occurs only when 
there is sufficient amount of oxygen. Consequently, hydroxylated HIF-1α subunits are 
preferably recognized by VHL and are tagged for ubiquitination and proteasomal degradation. 
In contrast, under hypoxic conditions, HIF-1α subunits hydroxylation does not occur and 
HIF-1α structure reaches a conformational stabilization in the cytoplasm. With these 
properties, HIF-1α is able to enter the nucleus and form a transcriptional complex with HIF-
1β subunit, p300 and CBP for binding hypoxia responsive elements (HREs) and to finally 
trigger the activation of hypoxia target genes, implicated in the regulation of several 
biological processes as cell proliferation and survival (Figure 3) (27). HIFs can transcribe 
more than 40 target genes (26), among which the carbonic anhydrase isoform 9 (CAIX), 
involved in increasing the metastatic potential of GBM by acidificating the tumor 
microenvironment, and Notch1, which leads to NFAT activation, cell proliferation and tumor 
growth. Thus, hypoxia sustains GBM cells proliferation, particularly preserving the stem 
population in the perivascular and hypoxic niches, by up-regulating other transcription factors 
like Notch and Oct4, which control self-renewal and multipotency of stem cells. Moreover, it 
has been described that HIF counteracts the differentiating stimuli induced by BMPs (28). In 
vitro hypoxia stimulates both the expression of the stem markers CD133, Nestin, Sox2, and 
the formation of neurospheres, characterized by elevated plurpotency (29–31). HIF is directly 
engaged in angiogenesis and tumor invasion, by activating several factors such as VEGF, 
metalloproteases, TGF factors and CXCR4 (3). 
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Figure 3. HIF-1α regulation by proline hydroxylation. In NORMOXIA, the alpha subunits of HIF (HIF-
1α) are hydroxylated at conserved proline residues by HIF prolyl-hydroxylases (PHD 1,2,3), allowing their 
recognition and ubiquitination by the VHL E3 ubiquitin ligase, which labels them for rapid degradation by the 
proteasome. In HYPOXIA, PHDs are inhibited, since they utilize oxygen as a co-substrate. HIF-1α subunits 
reach stabilization and enter the nucleus, where they form a complex with HIF-1β subunits, p300 and CBP to 
finally trigger the activation of hypoxia target genes which in turn regulate several biological processes, as cell 
proliferation and survival.  
 
During last years, lots of evidences have suggested that lowered oxygen tensions positively 
correlate with tumour aggressiveness (32,33) and over-activity of Hypoxia Inducible Factor-
1α (HIF-1α) is implicated in tumour progression (34). The correlation between hypoxia and 
tumor aggressiveness has been causally linked to increased genomic instability (35), but it is 
also related to increased survival of proliferating cells by suppression of p53 and its 
associated cell growth control (36). Importantly, hypoxia has been shown to promote de-
differentiation of neuroblastoma cells (33,37,38), suggesting that it may reinforce an 
environment for aggressive tumor growth. It may also prevent a pre-existing stem cell 
population from differentiating, which is important in light of increasing evidence that cancer 
is initiated by dysfunctional stem cells (39–41). Activated HIF-1α plays a crucial role also in 
the adaptive responses of the tumor cells to changes in oxygen through transcriptional 
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activation of over 100 downstream genes which regulate vital biological processes required 
for tumor survival and progression (27).  
 
Wnt/β-catenin/Tcf pathway 
 
Among the several pathways directly modulated by hypoxia, the Wnt/β-catenin/Tcf pathway 
is one of the most important, whose implication in tissue development and in the progression 
of several human cancers has been extensively investigated. Wnt signals play important roles 
during development (42), as well as in adult tissues that are refreshed and repaired by stem 
cells (43). It is the essential function of Wnt signaling in stem cell self-renewal and cell 
proliferation that links this pathway to problems of aging and disease such as cancer and 
diabetes (44,45). The core of the pathway is the E-cadherin cell-cell adhesion adaptor protein 
and the transcriptional co-regulator β-catenin (46). In the absence of WNT signaling, β-
catenin levels in the cytoplasm and nucleus are low as a result of continuous phosphorylation 
by the serine/threonine kinases CK1 (casein kinase 1) and GSK3β (glycogen synthase kinase 
3β), leading to binding of β-transducin-repeat-containing protein (βTRCP) and to 
ubiquitylation and degradation by the proteasome. The destruction complex is composed of 
CK1 and GSK3β, as well as the anchor proteins AXIN1 (axis inhibition protein 1) and APC 
(adenomatous polyposis coli). In the nucleus, members of the T-cell factor (TCF) family are 
bound by co-repressors such as GRG/TLE (Groucho/transducin-like enhancer) proteins that 
shut off expression of Wnt target genes. Other components of the repressor complex include 
CTbP (C-terminal binding protein) and HDACs (histone deacetylases). β-catenin in the 
nucleus is inhibited from binding TCF by ICAT (cell autonomous inhibitor of β-catenin and 
TCF). The Frizzled receptor complex is composed of Frizzled and LRP5 (LDL-receptor-
related protein 5) or LRP6 and can also be actively inhibited by receptor-bound soluble 
inhibitors such as DKK1 (Dickkopf homologue) (Figure 4A). When a lipid-modified WNT 
protein binds to the receptor complex, a signaling cascade is initiated. LRP is phosphorylated 
by CK1 and GSK3β, and AXIN1 is recruited to the plasma membrane. The kinases in the β-
catenin destruction complex are inactivated and β-catenin translocates to the nucleus where is 
able to bind TCF factors to form an active transcription factor complex. In the nucleus, co-
factors such as legless (LGS; also known as BCL9) and Pygopus (PYGO), CBP/p300, 
Brahma and MED12 are recruited to initiate transcription of a large set of target genes (Figure 
4B). To trigger the activation of these genes, the transcriptional effectors act downstream of 
the signaling pathway at the molecular level binding specific DNA sequences. These 
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transcriptional factors belong to the mammalian TCF/LEF family which encompasses LEF-1, 
TCF7 (also known as TCF1 but encoded by TCF7 gene), TCF3 (encoded by TCF7L1), and 
TCF7L2 (also known as TCF4 but encoded by TCF7L2 gene). Structural characterization 
studies revealed several functional domains which have been mapped on the TCF family of 
proteins. In particular, the high mobility group (HMG) DNA binding domain is the most 
highly conserved region of the TCF proteins (47,48). Like other HMG box-containing 
proteins, TCF/LEF proteins possess minimal transcriptional activity on their own and can 
efficiently affect transcription only by recruiting various binding co-factors, which, in turn, 
recruit chromatin modifiers to suppress or activate their target genes (46). In vitro studies with 
recombinant proteins revealed that TCF/LEF proteins recognize a core consensus sequence, 
the TCF/LEF DNA binding motif (49,50). Moreover, these monomers contain a domain that 
can interact with Armadillo repeats, which serve as the platform for β-catenin binding (51,52). 
Indeed, β-catenin binds TCF/LEFs through 3–10 Armadillo repeats and then uses its C 
terminus to interact with other co-factors, including the chromatin modifiers CBP/p300 and 
Brg1, which ensure the efficient transcription of their target genes (46).  
 
 
Figure 4. Canonical or WNT–β-catenin–TCF/LEF signaling. (A) In the absence of WNT signaling, β-catenin 
levels are maintained low by continuos ubiquitylation and degradation by the proteasome. In the nucleus, TCF 
(T-cell factor) molecules are bound by co-repressors such as GRG/TLE (Groucho/transducin-like enhancer) 
proteins that shut off expression of WNT target genes. (B) Upon binding of a lipid-modified WNT protein to the 
receptor complex, a signaling cascade is initiated and β-catenin translocates to the nucleus to form an active 
transcription factor complex with TCF, leading to transcription of a large set of target genes (53). 
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WNT pathway/hypoxia correlation and pro-differentiating strategies  
 
Recently, several studies proposed promising approaches to mild GSCs aggressiveness by 
inducing neuronal differentiation. Indeed, forcing GSCs to differentiate into neuronal cells as 
a mean to reduce tumor growth may represent a powerful tool to overcome treatment 
resistance. Guichet et al. explored the possibility to eliminate GSCs forcing their terminal 
differentiation overexpressing neurogenic transcription factors  involved in neurons formation 
processes. In vitro engineered GSCs encountered massive cell death, proliferation arrest and a 
drastic reduction of neurosphere formation. In vivo, GSCs were unable to form orthotopic 
tumors. By inducing cell death, cell cycle arrest or differentiation, it has been demonstrated 
that neurogenic proteins are able to oppose GSCs stem-like and non-stem-like cell growth 
(54).Using anticancer drugs may represents another promising approach to induce neuronal 
differentiation of GSCs. Indeed, it has been demonstrated that the anticancer drug taxol was 
able, not only to induce cell death in C6 glioma cells, but also morphological changes, 
including cell elongation, thinning of cellular processes, irregular shapes and fragmented 
nucleation or micronuclei in the survived C6 cells. These data suggested as taxol could induce 
the expression of neural differentiation markers and inspired that some anticancer drugs may 
be applied to elimination of the malignant cancer cells as well as changing proliferation and 
differentiation status of tumor cells (55). Another approach to reach this pro-differentiating 
purpose consists in exploiting the molecular pathway implicated in the regulation of CSCs 
phenotype. In this context, although the precise interactions between HIF-1α and the β-
catenin/TCFs complex are under evaluation, some observations suggest an important role for 
tissue hypoxia in regulating the Wnt/β-catenin/TCF signaling cascade and, subsequently, the 
GSCs phenotype. Interestingly, Wnt signaling has been suggested to regulate differentiation 
of normal neural progenitors, promoting neurogenesis in the murine adult hippocampus (56), 
an hypoxic brain zone where adult neural stem cell reside in mice and humans (57). In the 
same context, it has been demonstrated that hypoxia can promote canonical Wnt signaling 
activation and that HIF-1α enhances NSC differentiation and neuronal maturation by co-
operating with β-catenin activation (58). So far, it has been demonstrated that the interaction 
between HIF-1α and HIF-2α with β-catenin modulates TCF4-mediated transcriptional activity 
(59). Moreover, it has been reported that hypoxia (HIF-1α) is able to induce the over-
expression of β-catenin co-factors TCF1 and LEF-1, sustaining the activation of Wnt 
pathways. Conversely, in high oxygen conditions, TCF1 and LEF-1 expression decreased and 
TCF4 transcript resulted augmented, confirming the central role of HIF-1α in the regulation of 
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TCF/LEF-1 levels (58,60). Despite these observations in normal brain development, the role 
of Wnt activation in regulating brain tumour phenotype remains controversial. Previous 
studies showed that lithium (LiCl2) potently and specifically blocked glioma cell migration 
through inhibition of serine/threonine protein kinase glycogen synthase kinase-3 (GSK3), a β-
catenin inhibitor (61). Moreover, the use of other GSK3 inhibitors have been reported to 
increase β-catenin levels, thus down-regulating stem cell markers, such as Nestin and Sox2 
and increasing the fraction of cells expressing β-III-tubulin and GFAP in a cell line-dependent 
manner (62). A recent study demonstrated that Wnt activation promotes neuronal 
differentiation of GBM cancer cells under hypoxia, and that these effects are exerted by 
antagonizing Notch signaling, leading to up-regulation of pro-neuronal genes and inhibition 
of stemness-related pathways (60). In addition, Wnt activation promotes a dramatic 
differentiation of GBM cancer stem-like cells towards a neuronal, less aggressive phenotype 
(60). However, other authors reported that over-expression of Wnt in astrocytic glioma 
specimens promoted CSCs self renewal and proliferation (63–65). Another recent study 
pointed out as Wnt signaling was active in at least a subset of malignant gliomas and that 
inhibition of this pathway could slow tumor growth, reduce the stem-like cellular fraction, 
and block clonogenicity in some GBM neurosphere lines (66). Thus, the interaction between 
Wnt pathway and hypoxic signaling in brain tumours remain to be elucidated and needs a 
further deeper investigation in order to fully understand the impact of these signaling pathway 
in GBM tumor formation.  
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MAIN AIMS OF THE STUDY 
 
 
1. To characterize the role of the Wnt related transcription factors TCF1 (encoded by TCF7 
gene) and TCF4 (encoded by TCF7L2) in determining GBM phenotype. 
 
2. To elucidate the interaction between TCF1/TCF4 and the GBM microenvironment by 
exploiting multiple approaches: 
 
 Evaluation of the cooperation between the hypoxia factor HIF-1α and the TCFs 
transcription complex and how this interaction can modulate TCFs binding to the 
DNA. by ChIP experiments; 
 Study of the interaction between HIF-1α and the TCFs under Wnt pathway 
activation; 
 Analysis of GBM derived cells gene expression profile at different oxygen 
concentrations for genes related to Wnt pathway and neural cells phenotype. 
 
3. To correlate in vitro results in human GBM samples 
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RESULTS 
 
Microenvironmental oxygen tension differentially regulates GBM cell fate upon Wnt 
pathway intracellular activation 
Since the role of the secreted signaling proteins has been extensively debated for their effects 
on the phenotype of cancer cells, these recombinant molecules are nowadays considered as an 
interesting tool to be investigated for cancer therapy. Moreover, recent research point out the 
importance of the microenvironment in determining cancer cell  phenotype (67,68). Starting 
from these considerations, we derived primary GBM cells directly from patient’s biopsies, 
treated them with recombinant Wnt3a both at 2% oxygen (hypoxia, H) or either at 20% 
oxygen (normoxia, N) and assessed their response to Wnt pathway activation in these 
different microenvironmental conditions. Immunofluorescence analysis based on stemness 
(Nestin) and neuronal differentiation (β-III-tubulin) markers revealed that normoxia de-
sensitizes GBM cells to Wnt treatment compared to Wnt-treated cells in hypoxia, where cells 
are subjected to a strong neuronal differentiation, and confirmed our previous finding that a 
Wnt-mediated neuronal differentiation of primary GBM derived cells occurs only in hypoxia 
(60) (Figure 5A,B). We confirmed also that Wnt3a treatment and high oxygen tension are 
both able to decrease nestin expression, as previously reported (28,60) (Figure. 5A,B). 
 
Figure 5. Wnt pathway activation differentially modulates the phenotype of GBM cells depending on the 
oxygen tension. Primary GBM cells were initially expanded in 2% oxygen (hypoxia=H) or 20% oxygen 
(normoxia=N) and then acutely exposed(+) or not exposed (-) to Wnt3a (30ng/mL) for 96 hours (A) 
Representative immunofluorescence images of GBM cells stained for Nestin (green)/ β-III-tubulin (red) and 
DAPI (blu). (B) Bar graph reporting relative quantification of images described in panel (A). 
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Once the impact of Wnt pathway activation on cell phenotype has been recorded, we 
investigated its role on GBM cells proliferation and self-renewal capacity. Thus, the stem-like 
potential was assessed by serial dissociation and re-plating of GBM neurospheres and, 
interestingly, we found that the number of neurosphere decreased after Wnt pathway 
activation only in hypoxia (Figure 6A,B). On the other hand, we observed an opposite effect 
in normoxia, confirming the different effect of Wnt pathway activation depending on oxygen 
levels (Figure 6A,B). In addition, we measured the effects of Wnt pathway activation on 
GBM initiating cells frequency, depending on microenvironmental conditions. Indeed, we set 
up limiting dilution assays (LDAs) to assess the effect of Wnt pathway activation on GBM 
cells cultured at different oxygen levels and treated with Wnt3a. We observed that Wnt3a 
treatment significantly decrease the frequency of self-renewing GBM cells at low oxygen 
levels with an opposite effect at high oxygen levels, where GBM stem cells frequency even 
increased (Figure 6C). More specifically, the frequency of GBM initiating cells was measured 
for all the microenvironmental conditions and we obtained these values: 1/30 for GBM cells 
cultured in hypoxia, 1/282 for GBM cells cultured in hypoxia and treated with Wnt3a, 1/368 
for GBM cells cultured in normoxia and 1/56 for GBM cells cultured in normoxia and treated 
with Wnt3a. These evidences confirmed the impact of Wnt pathway activation on GBM cells 
cultured in hypoxia in terms of a negative regulation of self-renewal potential, and induction 
of a neuronal differentiation process, thus prompting us to hypothesize the existence of an 
opposing phenotypic effect that could be engaged by Wnt signaling activation depending on 
the microenvironmental oxygen. 
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Figure 6. Wnt pathway activation differentially affects self-renewal capacity of GBM cells depending on 
the microenvironment. (A) Representative images of primary GBM cells expanded as neurospheres for 1 week 
in 2% oxygen (hypoxia=H) or 20% oxygen (normoxia=N) and then acutely exposed to Wnt3a (30ng/mL) for 96 
hours. (B) Bar graphs represent the number of GBM derived neurospheres formed after dissociation and 
replating for 3 times. Mean of 3 tumors ± S.E.M. (C) Limiting dilution assay of GBM cells expanded in 2% 
oxygen (hypoxia=H) or 20% oxygen (normoxia=N) and then acutely exposed to Wnt3a (30ng/mL).  
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Wnt pathway activation induces the formation of a TCF1/-catenin/HIF-1molecular 
complex at low oxygen tension 
Since the Wnt pathway activation was able to mediate two different phenotypic effects at 
different oxygen levels in GBM cells, we were interested in dissecting the molecular basis 
underlying the above mentioned effects. Thus, we analyzed the proteins levels of the -
catenin co-factors TCF1, TCF4 and their relationship with the known hypoxia sensor HIF-1α. 
Through WB analysis we observed, as expected, that TCF1 expression is strongly induced 
after Wnt pathway activation both in hypoxia and normoxia (60). Interestingly, we found that 
TCF4 expression was oxygen dependent with higher protein levels at 20% O2 (Figure 7A). 
Moreover, WB showed that the more abundant TCF4 isoforms expressed by GBM cells are 
the full length (75kDa, putative TCF4E isoform) (69), whose function has been described to 
be inhibitory (70). Of note, the lower molecular weight TCF4 isoforms were barely 
detectable. To better characterize the expression data of TCF1 and TCF4, we set up 
immunofluorescence experiments which confirmed the results obtained with western blot 
analysis (Figure 7B).  
 
 
Figure 7. Wnt pathway transcriptional effectors are differentially expressed in hypoxic and normoxic 
GBM cells. Primary GBM cells were initially expanded at 2% oxygen (hypoxia=H) or 20% oxygen 
(normoxia=N) and then acutely exposed(+) or not exposed(-) to Wnt3a (30ng/mL) for 24 hours (A) 
Representative western blot analyses of HIF1-catenin, TCF1 and TCF4 along with β-actin as loading 
control; 3 different GBM have been analyzed. (B) Representative immunofluorescence images of primary GBM 
cells stained for TCF1(red) and TCF4 (red) and DAPI (blu). 3 different GBM have been analyzed. bar=50µm 
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To unveil the molecular interactions of these transcription factors in different 
microenvironmental conditions, we immunoprecipitated -catenin and HIF-1in cells treated 
with Wnt3a and either maintained in hypoxia or normoxia. TCF1 and TCF4 differentially 
bound to -catenin in GBM cells grown at different oxygen tensions, giving also a meaning to 
the variable expression of TCF1 and TCF4 depending on oxygen levels, previously reported 
by our group (60). In particular, we demonstrated that TCF1 bound to -catenin at both 2% 
and 20%O2 after Wnt3a administration (Figure 8A). while the more expressed isoform of 
TCF4 in GBM cells was curiously not associated to -catenin (Figure 8A) Similarly, TCF1 
immunoprecipitated with HIF1in hypoxia only after Wnt3a treatment with TCF4 showing 
absence of binding also to HIF1Figure 8B). 
 
 
Figure 8. Wnt pathway transcriptional effectors bind different co-factors depending on the oxygen 
tension. Primary GBM cells were initially expanded in 2% oxygen (hypoxia=H) or 20% oxygen (normoxia=N) 
and then acutely exposed(+) or not exposed(-) to Wnt3a (30ng/mL) for 24 hours (A) Representative images of 
GBM cells immunoprecipitates extracted with β-catenin antibody and analyzed by western blotting with HIF-
1CF1 and TCF4antibodies (numbers represent kDa). (B) Representative images of GBM cells 
immunoprecipitates extracted with HIF-1antibody and analyzed by western blotting with HIF-1CF1 and 
TCF4antibodies. 3 different GBM have been analyzed.  
 
With these experiments, we demonstrated the existence of a molecular complex activated by 
Wnt3a administration in hypoxia composed by TCF1, -catenin and HIF-1αand probably 
responsible for the neuronal differentiation process (Figure 9A). On the other hand, in 
response to high oxygen levels, we observed a strong increase of high MW TCF4 isoforms 
(TCF4E) which were not able to bind neither -catenin nor HIF-1Given its reported 
inhibitory role on transcription and the documented lack of neuronal differentiation of GBM 
cells in normoxia, we hypothesized that TCF4E could repress the process of neuronal 
differentiation engaged by GBM cells after hypoxic Wnt activation (Figure 9B). 
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Figure 9. Proposed molecular model of the neuronal differentiation process mediated by Wnt pathway 
activation in GBM. (A) HYPOXIA: Wnt pathway activation triggers the formation of a molecular complex 
formed by TCF1, β-catenin and HIF-1α which induces the neuronal differentiation of GBM cells towards 
neurons. (B) NORMOXIA: neuronal differentiation of GBM cells is impaired by the inhibitory action of TCF4E 
isoforms which block the neuronal commitment observed at low oxygen levels in the presence of HIF-1α.  
 
Hypoxia cooperates with Wnt pathway to regulate the transcriptional milieu of GBM 
cells 
A well accepted paradigm in molecular biology is that gene transcription is induced or 
repressed by transcription factors that, by recruiting others co-factors, form complexes on the 
genome to activate or inhibit target genes. Thus, it is important to know the position of these 
transcription factors and how they are combined on specific regions of the genome to 
understand their regulation on gene expression. Once demonstrated the existence of a 
molecular complex formed by TCF1, -catenin and HIF-1 triggered by Wnt pathway 
activation, we assessed the impact of this complex on the transcriptional landscape of GBM 
cells. Thus, we performed ChIP-sequencing experiments in which we immunoprecipitated 
HIF-1TCF1 and TCF4 and analyzed the genomic sequences they were bound to, at 
different oxygen tensions. 
First, we examined the general binding pattern of HIF-1TCF1 and TCF4 on the genome in 
cells maintained in hypoxia and treated for 24 hrs with Wnt3a and the general binding pattern 
of TCF4 on the genome in cells acutely expose to normoxia upon Wnt activation (Figure 
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10A). Of note, from cells acutely exposed to 20% oxygen we could not retrieve interpretable 
high-quality peak calls from ChIP-seq data from HIF-1α and TCF1, thus excluding these data 
from further analysis. In particular, heatmaps showing the chromatin features of each 
transcription factor revealed genomic areas of co-binding between HIF-1and TCF co-
factors. Interestingly, TCF4 showed a different genomic binding pattern in hypoxia compared 
to normoxia (Figure 10A). All the transcription factors analyzed bound different genomic 
regions and 17% of called sequences resulted to be promotorial (Figure 10B). We then 
examined how TCFs co-factors were arranged on the genome after Wnt activation at 2% 
oxygen and their mutual relationship. We confirmed that TCF1 and TCF4 localized in 
genomic regions spanning approximately 2kb around Transcriptional Starting Sites (TSS) 
(Figure 10C) of genes involved in the regulation of metabolic and transcriptional processes 
(Figure 10D). 
 
Figure 10. The binding pattern of TCFs on the genome depends on microenvironmental conditions. 
 (A) Heatmaps showing the chromatin features within 250 bases around the top 50 peaks for each TF; the peaks 
were selected for showing both the higher fold-enrichments and the lower p-values. (B) Molecular 
characterization of the genomic regions bound by the different TF found in (A). Bi-dimensional dot plot 
reporting the peak positions for pairs of TFs in relation to the TSS of genes on the genome of GBM cells, after 
WNT pathway activation; level-lines identify the regions of higher dot densities for each TF. (C) HYPOXIA 
(H): TCF1 paired with TCF4 (D) Gene Ontology (GO) analysis of genes in common for TCF1 and TCF4 in 
hypoxia.  
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Then, we tried to characterize the transcriptional cooperation between TCFs co-factors and 
HIF-1 in hypoxia. In particular, we observed that HIF-1and TCF1 co-localized on the 
genome very close to TSS of genes which were also targeted by TCF4, but in different, and 
more distal (≈ +3kbp) sequences (Figure 11A). The gene list retrieved from this analysis, 
revealed that HIF-1TCF1 and TCF4 together, regulate genes involved in neurogenesis and 
neuron differentiation processes as emerged by GO analysis (Figure 11B) and corroborating 
our phenotypic results on hypoxic Wnt3a–treated GBM cells (Figure 5A) Surprisingly, 
investigating the binding pattern of TCF4 in GBM cells exposed to high oxygen levels 
(normoxia), we discovered that TCF4 was seated above the same genomic regions bound by 
HIF-1and TCF1 in hypoxia (Figure 11C) thus originating a very similar GO analysis, 
showing its involvement in genes regulating the neuronal differentiation process as well 
(Figure 11D). 
 
Figure 11. Wnt pathway transcriptional effectors trigger the activation of specific genes depending on the 
microenvironment. Bi-dimensional dot plot reporting the peak positions for pairs of TFs in relation to the TSS 
of genes on the genome of GBM cells, after WNT pathway activation; level-lines identify the regions of higher 
dot densitites for each TF. (A) HYPOXIA (H): TCF1 paired with HIF-1α (red), and TCF4 paired with HIF11-α 
(green) (B) Gene Ontology (GO) analysis of genes in common for TCF1 and HIF-1α in hypoxia (C) 
NORMOXIA (N): TCF4 paired with HIF-1α (blue). (D) Gene Ontology (GO) analysis of genes in common for 
TCF4 and TCF1/HIF-1α in normoxia. 
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Taken together, these data prompted us to hypothesize a molecular model of the 
transcriptional control exerted by TCFs co-factors depending on the microenvironmental 
oxygen tension in GBM cells. In particular, our data suggest that low oxygen levels (HIF-
1stabilization) together with Wnt stimulation, support the formation of a HIF-1α/TCF1 
molecular complex (Figure 8B) which triggers several genes involved in the neuronal 
differentiation processes (Figure 11A,B). On the other hand, high oxygen levels promote HIF-
1α degradation and favor the expression of TCF4 isoforms endowed with an inhibitory 
function to be exerted against the same neuronal differentiation genes activated by the HIF-
1α/TCF1  complex in hypoxia. (Figure 11C,D). Indeed, when we limited our analysis on the 
genes specifically bound by HIF-1α/TCF1 in hypoxia (a 40bp genomic region containing a 
HIF-1α/TCF1 co-localization binding site flanked by an additional 40bp region in which 
TCF1 and HIF-1α are positioned in sequence spanning 10bp from each other) (Figure 12A) a 
significant neurogenesis/neuron development-related GO was obtained (Figure 12B), thus 
corroborating their central role in inducing neuronal differentiation. Moreover, when we 
intersected this gene list with a series of genes putatively controlled by TCF4 in normoxic 
conditions, we generated a gene signature (91 genes) with a peculiar expression pattern across 
glioma samples of different grade and thus able to distinguish them from normal brain 
samples in an unsupervised analysis (Figure 12C) . More importantly, we intriguingly found 
that genes consistently down-regulated in GBM compared to normal brain (n=54) were 
significantly involved in neurogenesis and neuron specification processes (Figure 12D). On 
the contrary, up-regulated genes were mainly related to transcriptional regulatory mechanisms 
(Figure 12E).  
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Figure 12. Gene signature obtained from TCF1/HIF-1α co-regulated genes is diffentially expressed in 
gliomas of different grade. (A) Cumulative ChIP-seq profiles of all the TFs around the peaks showing the HIF-
1α /TCF1 co-localization under hypoxic conditions. (Red: TCF1 2% oxygen; Black: HIF-1α 2% oxygen; Green: 
TCF4 2% oxygen; Blue: TCF4 20% oxygen) (B) Gene Ontology (GO) analysis of genes containing a HIF-
1α/TCF1 co-localization binding (C) Heatmap generated by un-supervised analysis of HIF-1α /TCF1 common 
regulated genes and bound by TCF4 in normoxia applied on the GSE4290 dataset (71) (D) Gene Ontology (GO) 
analysis of down-regulated genes derived from (C). (E) Gene Ontology (GO) analysis of up-regulated genes 
derived from (C). 
 
In order to functionally validate these observations, we focused on the genes mainly down-
regulated in GBM relative to normal samples, showing their progressive reduction of 
expression with increasing glioma grade (Figure 13A,B). Importantly, a series of three 
representative genes (CHRM3, CMIP, LRP1B) resulted to be dramatically up-regulated upon 
Wnt3a stimulation only in hypoxia, thus validating our hypothesis (Figure 13C). 
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Figure 13. TCF1/HIF-1α co-regulated genes are down-regulated in GBM, but strongly activated by 
hypoxic Wnt stimuli. (A) Level plot representing the median fold change, normalized on normal brain, of the 
20 more down regulated genes in GBM from heat map in figure 12C. (B) mRNA expression level of three 
representative genes comparing normal brain with glioma samples of different grade. (C) RQ-PCR analysis of 
the same gene as in (B) at different time points of Wnt3a treatment both in hypoxia and normoxia. 3 different 
GBM have been analyzed.  
 
Our results suggest that the balance between cell differentiation and the maintenance of an 
undifferentiated phenotype is regulated in GBM by an oxygen-dependent mechanism which 
involves a fine molecular tune of TCFs co-factors and HIF-1α. (Figure 14). 
 
Figura 14. Proposed model for the transcriptional regulation mediated by Wnt pathway effectors 
depending on microenvironmental oxygen tension. (A) HYPOXIA: Wnt pathway activation (Wnt3a 
treatment) induces the switch of GBM cells toward neurons activating the expression of genes implicated in 
neuronal differentiation processes. Upon low oxygen levels, HIF-1α is stabilized and binds to TCF1. This 
complex sits on promotorial regions close to TSS and activates genes related to neuronal differentiation 
processes. On the other hand, TCF4 binds to HIF-1α and sits on distant regions not affecting transcription of 
neuronal differentiation dependent genes. (B) NORMOXIA: Wnt pathway activation (Wnt3a treatment) does not 
induce the switch of GBM cells toward neurons. Upon high oxygen levels, HIF11-α is degradated, TCF4 is free 
to sit on the same promotorial regions bound by the molecular complex in hypoxia and inhibit the same genes 
related to neuronal differentiation processes. 
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TCF4 expression is increase by high oxygen levels and exerts a transcriptional inhibitory 
function in GBM cells 
ChIP sequencing results strongly support the hypothesis of a peculiar role of HIF-
1andTCF1 in mediating the neuronal differentiation of GBM cells observed at low oxygen 
levels upon Wnt stimulation. On the other hand, dissecting the molecular mechanisms 
underlying the behavior of GBM cells at higher oxygen levels represents a more complicated 
challenge. ChIP sequencing data give strength to the hypothesis that TCF4 may exert an 
inhibitory action against neuronal differentiation in this context. For these reasons, we needed 
to functionally validate these results in GBM cells. To this end, we set up knockdown 
experiments in which we abolished TCF1 or either TCF4 expression in primary GBM cells in 
vitro, showing that both TCF1 and TCF4 specific siRNAs were able to strongly decrease their 
mRNA and protein expression levels in primary GBM cells (Figure 15).  
 
 
Figura 15. TCF1 and TCF4 knockdown efficiency in GBM cells. Representative images of protein expression 
and mRNA expression levels of TCF1 and TCF4 in GBM cells after treatment with specific siRNA, assessed by 
western blotting and RQ-PCR, respectively. siNEG was used as negative control of knockdown. β-actin was 
used as loading control. 
 
Primarily, in order to verify the supposed inhibitory function of TCF4 against neuronal 
differentiation, we transfected TCF4-silenced GBM cells with a luciferase-based Wnt 
signaling reporter plasmid (BAT-lux) and assessed the impact of TCF4 levels on Wnt 
pathway activation. TCF4 knockdown significantly increased the responsiveness of BAT-lux 
upon Wnt stimulation in both hypoxia and normoxia, confirming the presence of a TCF4-
mediated suppression of Wnt signaling Figure 16A). Then, we investigated the impact of 
TCF4 knockdown on the phenotype of GBM cells through immunofluorescence analysis. As 
anticipated by previous data, TCF-silenced cells showed a potent induction of Wnt-mediated 
neuronal differentiation also in normoxia Figure 16B), with a significant decrease of Nestin 
expression together with a strong increase of the amount of β-III-tubulin+ cells (Figure 
16C,D). 
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Figure 16. TCF4 knockdown induces neuronal differentiation of GBM cells upon Wnt pathway activation 
at high oxygen tensions. Primary GBM cells were initially expanded in 2% oxygen (hypoxia=H) or 20% 
oxygen (normoxia=N),  transfected with a luciferase-based Wnt pathway reporter plasmid (BAT-lux), silenced 
for TCF4 and then acutely exposed(+) or not exposed(-) to Wnt3a (30ng/mL) for 24 hours (A) Graph bar 
representing the luciferase relative light units (RLU) in GBM cells. Data were normalized to the control siNEG. 
3 different GBM have been analyzed. (B) Representative immunofluorescence images of GBM cells stained for 
Nestin (green)/ β-III-tubulin (red) and DAPI (blu). 3 different GBM have been analyzed and siNEG was used as 
control. (C) (D) Bar graph reporting the percentage of positive cells for Nestin and β-III-tubulin, respectively, in 
relation to images described in panel (B) Hypoxia(H), Normoxia(N).  
 
We then further validated the inhibitory function of TCF4 by over-expressing a 75kDa 
isoform of TCF4 (TCF4E) and evaluating its ability to suppress the HIF1a/TCF1-mediated 
induction of neuronal differentiation in hypoxic conditions. Western blot confirmed the 
presence of TCF4E protein after transient plasmid transfection of GBM cells (Figure 17). 
Moreover, we demonstrated that TCF4E over-expression was sufficient to completely block 
the initiation of the neuronal differentiation process normally engaged after Wnt pathway 
activation in hypoxia (Figure 18A). Indeed, high levels of TCF4E brought the levels of 
Nestin+ and β-III-tubulin+ cells back to a control condition (hypoxic non-stimulated cells). 
(Figure 18B,C).  
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Figure 17. Transient transfection of the inhibitory isoform TCF4E (75kDa) in GBM cells. Representative 
images of protein expression and mRNA expression levels of TCF4 in GBM cells after transient transfection 
with the inhibitory isoform TCF4E (75kDa), assessed by western blotting and RQ-PCR, respectively. pcDNA3.1 
was used as negative control of transfection. β-actin was used as loading control. 
 
 
Figure 18. TCF4E over-expression blocks the neuronal differentiation of GBM cells upon Wnt pathway 
activation at low oxygen levels. Primary GBM cells were initially expanded in 2% oxygen (hypoxia=H) or 20% 
oxygen (normoxia=N),  transfected with the inhibitory isoform TCF4E and then acutely exposed(+) or not 
exposed (-) to Wnt3a (30ng/mL) for 96 hours (A) Representative immunofluorescence images of GBM cells 
stained for Nestin (green)/ β-III-tubulin (red) and DAPI (blu). 3 different GBM have been analyzed and 
pcDNA3.1 empty vector was used as control. (B) (C) Bar graph reporting the percentage of positive cells for 
Nestin and β-III-tubulin, respectively, in relation to images described in panel (A). 
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Altogheter, these functional experiments confirm the hypothesis that TCF4 may exert an 
inhibitory function on the process of Wnt-mediated neuronal differentiation of GBM cells 
observed at low oxygen levels.  
 
HIF-1α and TCF4 display opposing functions in response to Wnt signaling activation 
So far, we demonstrated that in normoxia Wnt pathway activation is not able to switch the 
phenotype of GBM cells towards neurons and that this phenomenon is mainly due to a TCF4-
dependent inhibition of the expression of a specific gene signature. Conversely, high levels of 
HIF-1α ensure a proper Wnt-dependent induction of neuronal differentiation. To deepen these 
opposing mechanisms involved in the control of GBM cell phenotype, we overexpressed a 
constitutive active form of HIF-1α (pcDNA-HIF-1αΔODD) in GBM cells cultured in 
normoxia, and concomitantly modulated TCF4 levels by gene silencing approaches (Figure 
19).  
 
 
Figure 19. Transient transfection of pcDNA-HIFΔODD as a constitutive activated form of HIF-1α 
together with TCF4 silencing in GBM cells. Representative images of protein expression assessed by western 
blotting in GBM cells after transient transfection with pcDNA-HIF-1αΔODD (constitutive activated form of 
HIF-1α) and treatment with siTCF4. siNEG was used as negative control of knockdown. β-actin was used as 
loading control. HIFΔODD mutated protein has a lower molecular weight respect to native HIF-1α protein., due 
to lack of the portion which drive degradation of native protein at high oxygen levels. 
 
In this context, we confirmed once again that TCF4 suppression re-sensitizes GBM cells to a 
WNT-dependent induction of differentiation even in high oxygen conditions (Figure 20A; left 
panels). More importantly, we show that a strong ectopic expression of HIF-1α was sufficient 
to partially initiate the neuronal differentiation process (Figure 20A; right panels) and that 
suppressing TCF4 in these cells almost 80% of GBM cells acquired a neuronal differentiated 
phenotype and with a dramatic loss of nestin expression (Figure 20B,C).  
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Figure 20. TCF4 knockdown, together with HIF-1α induction, induces a strong neuronal differentiation of 
GBM cells at high oxygen levels. Primary GBM cells were initially expanded in normoxia, transfected with 
pcDNA-HIF-1αΔODD, silenced for TCF4 and then acutely exposed(+) or not exposed(-) to Wnt3a (30ng/mL) 
for 96 hours (A) Representative immunofluorescence images of GBM cells stained for Nestin (green)/ β-III-
tubulin (red) and DAPI (blu). 3 different GBM have been analyzed. pcDNA3.1 and siNEG were used as negative 
control of transfection and silencing, respectively. (B) (C) Bar graph reporting the percentage of positive cells 
for Nestin and β-III-tubulin, respectively, in relation to images described in panel (A).  
 
These results depict an interesting scenario in which:  
1. HIF-1α represents a potent co-factor in order that an efficient neuronal switch of GBM 
cells should be induced; 
2. TCF4 exerts a strong inhibitory function in suppressing the Wnt-mediated pro-
differentiation stimuli. 
   
38 
 
TCF1 co-factor is the master regulator of neuronal differentiation in GBM cells 
Once characterized the role of TCF4 in governing the balance between stemness and 
differentiation in GBM cells we further deepened the contribute of TCF1 in triggering the 
activation of neuronal genes in peculiar (hypoxic) microenvironmental conditions.  
In the same way as for TCF4, we confirmed that TCF1 acts as an activator of the Wnt 
signaling cascade by using the BAT-lux-based luciferase assay. Indeed, TCF1 knockdown 
significantly attenuated the Wnt-induced signaling activation in both hypoxia and normoxia 
(Figure 21A). Since we demonstrated that TCF1 can bind to HIF-1α in hypoxic conditions 
(Figure 8B) and that they are able to co-localize upon the same genomic regions (Figure 
11A), we tried to understand how HIF-1α can seat to TCFs consensus sequences and the 
mechanism by which they trigger the activation of neuronal differentiation genes. To this end, 
we transfected GBM cells with the BAT-lux reporter construct (containing a 7xTCF/LEF 
consensus repetition), and then performed ChIP-droplet digital PCR (ChIP-ddPCR) 
experiments in which we immunoprecipitated HIF-1a and amplified the cross-linked plasmid 
sequences with specific primers flanking the Wnt-responsive promotorial region (Figure 
21B). Wnt administration in hypoxia strongly promoted the binding of HIF-1α to the 
TCF/LEF consensus sequences compared to untreated or either normoxic cells (Figure 21C). 
In addition, the specific binding of HIF-1α to TCF/LEF consensus has been significantly 
impaired by TCF1 silencing, (Figure 21D) suggesting that HIF-1α is recruited by TCF1 in 
order to generate a molecular complex able to bind the TCF/LEF consensus on the genome 
and activate a differentiation program. 
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Figure 21. TCF1 knockdown decreases Wnt signaling pathway activation and impairs HIF-1α localization 
onto TCF/LEF consensus sequences. Primary GBM cells were initially expanded at 2% oxygen (hypoxia=H) 
or 20% oxygen (normoxia=N),  transfected with a luciferase-based Wnt pathway reporter plasmid (BAT-lux), 
silenced for TCF1 and then acutely exposed(+) or not exposed(-) to Wnt3a (30ng/mL) for 24 hours. (A) Graph 
bar representing the luciferase relative light units (RLU) in GBM cells. Normalization of the data to the control 
siNEG was done. 3 different GBM have been analyzed. siNEG was used as negative control. (B) Graphic model 
of the 7X TCF/LEF binding site based BAT-lux reporter used for analyzing binding of co-factors on consensus 
sequence in GBM cells (C) Graph bar representing relative enrichment over input obtained with ddPCR from 
GBM cells transfected with 7X TCF/LEF binding site based BAT-lux reporter (B) and immunoprecipitated for 
HIF1-α. Hypoxia (H), Normoxia (N). (D) Graph bar representing relative enrichment over input obtained with 
ddPCR from GBM cells transfected with 7X TCF/LEF binding site based BAT-lux reporter, immunoprecipitated 
for HIF-1α and silenced for TCF1. siNEG was used as control. 
  
Once again, we functionally validated this hypothesis by analyzing the phenotypic changes 
associated to TCF1 silencing in both hypoxia and in normoxia. Immunofluorescence analysis 
confirmed that, in hypoxia, TCF1-deficient cells were not able to differentiate toward the 
neuronal lineage upon hypoxic Wnt-stimulation (Figure 22A-C). Confirming previous results, 
at high oxygen levels, GBM cells phenotype was not affected by the modulation of TCF1 
levels (Fig.22A-C).  
All these data definitively sustain the fundamental role played by the microenvironment, and 
in particular by the oxygen tension and its sensor HIF-1α, in governing the phenotypic switch 
triggered by Wnt pathway activation in GBM cells. Indeed, activating Wnt pathway signaling 
through soluble molecules can push GBM cells to undergo phenotypic modifications, tightly 
regulated by the coordinated action of different transcription factors and transcriptional 
adaptors, which exert opposing role in balancing fundamental developmental stimuli such as 
stemness maintenance and neurogenic differentiation.  
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Figure 22. TCF1 knockdown blocks neuronal differentiation of GBM cells upon Wnt pathway activation 
at low oxygen levels. Primary GBM cells were initially expanded at 2% oxygen (hypoxia=H) or 20% oxygen 
(normoxia=N),  silenced for TCF1 and then acutely exposed(+) or not exposed(-) to Wnt3a (30ng/mL) for 96 
hours (A) Representative immunofluorescence images of GBM cells stained for Nestin (green)/ β-III-tubulin 
(red) and DAPI (blu). 3 different GBM have been analyzed. siNEG was used as control. (B) (C) Bar graph 
reporting the percentage of positive cells for Nestin and β-III-tubulin, respectively, in relation to images 
described in panel (A). 
 
TCF1/HIF-1α expressions positively correlate with a neuronal phenotype of GBM 
patients  
Once demonstrated the pivotal function of TCF1 as the principal mediator of the neuronal 
differentiation process in hypoxic GBM cells, we sought to investigate if TCF1 expression 
may correlate with an increased neuronal phenotype in series human GBM tumors. We 
evaluated TCF1 expression by immunohistochemistry in 142 GBM samples derived from 71 
different patients and correlated its levels, with the amount of HIF-1α and β-III tubulin 
staining in these tumors. Interestingly, showing no TCF1 protein expression also displayed 
very low levels of β-III tubulin and HIF-1α whereas tumors characterized by a strong 
expression of TCF1 demonstrated a marked staining of both β-III tubulin (Figure 23A) and 
HIF-1α (data not shown). Importantly, when we subdivided GBM samples based on their 
TCF1 expression (TCF1+ versus TCF1-) we found that the group of TCF1+ biopsies was 
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significantly enriched in β-III-tubulin-highly expressing samples (Figure 23B). Moreover, 
these TCF1+ samples positively correlated with the expression of high levels of HIF-1α 
(Figure 23C).  
 
Figure 23. TCF1 expression positively correlates with β-III tubulin and HIF-1α in a cohort of GBM 
patient samples. (A) Representative immunohistochemistry images of 5μm sections of paraffin embedded GBM 
specimens stained for TCF1 and β-III tubulin. n= 142 brain tumors samples were analyzed. (B) Graph bar 
representing the percentage of glioma samples negative(TCF1neg) or positive(TCF1pos) for TCF1 and expressing 
(β-III-tub medium/high) or not (β-III tubulin absent/low) β-III-tubulin. (C) Graph bar representing the positivity 
score of HIF-1α for samples negative (TCF1neg) or positive(TCF1pos) for TCF1. 
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As a confirmation, immunofluorescence experiments demonstrated that TCF1 and β-III-
tubulin co-localized TCF1 expressing tumors (Figure 24A), pointing at TCF1 as a 
fundamental mediator of neuronal differentiation also in this less artificial context.  
Finally, we tried to correlate each other all the 3 factors analyzed (TCF1, HIF-1α and β-III-
tubulin) by comparing TCF1 and HIF-1α scores with β-III tubulin expression levels. 
Integration of IHC data disclosed that TCF1, despite being heterogeneously expressed in 
GBM biopsies (from score 0 to score 15), it significantly and positively correlated to both β-
III tubulin expression and HIF-1α score as shown by the principal components analysis (PCA) 
in Figure 24 C.  
 
Figure 24. TCF1/HIF-1α expressions positively correlates with β-III tubulin in a cohort of GBM patient 
samples. (A) Representative immunofluorescence images of GBM patients specimens stained for β-III 
tubulin(red), TCF1(green) and DAPI(blu). (B) Graphs representing the correlation between TCF1 and HIF-1α 
scores in relation with β-III tubulin expression. Blu graph: samples with high HIF-1α score and low TCF1 score 
are correlated with a low/absent β-III tubulin expression. Green graph: samples with low HIF-1α score and high 
TCF1 score are correlated with a medium β-III tubulin expression. Red graph: samples with high HIF-1α score 
and high TCF1 score are correlated with a high β-III tubulin expression (C) Tridimensional model representing 
correlation between TCF1, HIF-1α and β-III tubulin expression in the GBM patient cohort 
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In particular, we faced three different scenarios: 
1. samples showing absent/low expression of β-III tubulin were characterized by 
relatively high HIF-1α scores but low TCF1 (Figure 24B upper panel);  
2. intermediate β-III tubulin expression correlated with absent/low HIF-1α but relatively 
high TCF1 scores (Figure 24B medium panel); 
3. neuronal differentiated samples expressing high levels of β-III tubulin displayed a 
synchronized high positivity for both HIF-1α TCF1 (Figure 24B lower panel). 
 
These data sustain the molecular model we characterized in vitro in which HIF-1α and TCF1 
should act together and in synchrony in order to induce a neuronal phenotypic switch of GBM 
cells.  
  
44 
 
DISCUSSION 
 
GBM represents a dramatic challenge for clinicians and researchers and, despite lots of efforts 
in trying to understand the mechanisms underlying GBM aggressiveness, a more complete 
knowledge of its biology needs to be achieved. GBM is a highly proliferative and invasive 
tumor with a significant tendency to infiltrate surrounding normal brain parenchyma, thus 
frustrating the complete resection of GBM tumor mass (2). Moreover, radiotherapy and 
chemotherapy can often be considered only as palliative treatments, making the clinical 
management of these tumors extremely difficult. 
GBM aggressiveness has been demonstrated to be sustained by a subpopulation of cells 
endowed with stem-like characteristics, cancer stem cells (CSCs) which plays a pivotal role 
also in treatment resistance and tumor recurrence (11). Microenvironmental conditions are 
peculiar to maintain the undifferentiated phenotype of CSCs and, in particular, oxygen tension 
is crucial to direct the fate of these cells. Indeed, it has been previously demonstrated by our 
group that GBM grows as an organized entity that we described as a three-layer concentric 
model in which the central hypoxic niche hosts CSCs, whereas the more differentiated cells 
reside in the external normoxic layers (9). The organized growth of GBM tumor mass is 
regulated by several signals deriving by cancer cells themselves and from the 
microenvironment. In this context, it has been previously demonstrated as hypoxia is 
fundamental to sustain GBM cells proliferation, particularly preserving the stem population in 
the perivascular and hypoxic niches, by activating specific transcription factors such as 
Notch1 which leads to NFAT activation and cell proliferation and tumor growth (26) or by 
up-regulating other transcription factors like Notch and Oct4, which control self-renewal and 
multipotency of stem cells. Moreover, we previously demonstrated that hypoxia cooperates 
with Wnt pathway to control GBM cell phenotype in terms of induction of neuronal 
differentiation. In particular, we underlined that Wnt pathway activation is able to induce the 
neuronal differentiation of GBM cells only in hypoxia, condition that maintain high levels of 
the hypoxia inducible factor HIF-1α. This process strictly depends on oxygen tension and is 
efficient in attenuating GBM cells aggressiveness (60).  
In this study, we investigated a tightly regulated mechanism by which canonical Wnt pathway 
and hypoxia cooperate to induce a reminiscent neuronal differentiation of GBM cells. In 
particular, we focused on dissecting the role of β-catenin/TCF1/TCF4 transcriptional complex 
and its interaction with the hypoxia sensitive transcription factor HIF-1α in deciding GBM 
cell fate depending on microenvironmental oxygen tension. Indeed, recent literature point out 
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the importance of complex transcriptional machineries in determining cellular fate both in 
normal tissues and cancer (72–74). Of note, they exert their intracellular function by 
modulating gene expression profile, which in turn determined the identity of cells (75,76). 
Moreover, the main regulator of these machineries is the microenvironment where cells are 
located, from which cells receive signals through the plasmatic membrane and then transduce 
them to the nucleus (77,78). In GBM, the role of the canonical Wnt pathway β-
catenin/TCF1/TCF4 complex has been extensively debated (60–66) but the specific 
interactions of different co-factors and how they respond to external microenvironmental 
stimuli has never been fully elucidated. Here, we demonstrate that oxygen tension has a 
strong impact in GBM cell response to Wnt activation. In particular, we found that 2% 
oxygen determine a pro-differentiative effect upon Wnt signaling activation. Conversely, 20% 
oxygen gives to Wnt pathway a pro-oncogenic function as emerged by the neurosphere 
forming and the limiting dilution assays (Figure. 6). Our attention was then attracted by the 
transcription factor TCF4, that, surprisingly, not only resulted to be up regulated in normoxia, 
compared to 2% oxygen, but also was not able to bind nor β-catenin neither HIF-1α (79). This 
intriguing data, prompted us to deepen the role of TCF4 in GBM biology and to hypothesize 
that it can exert an inhibitory function on gene transcription. It has previously been described 
in colorectal cancer that the higher molecular weight isoforms of TCF4 (i.e. TCF4E) contain 
specific DNA binding domain with an inhibitory function (70). Of note, in GBM cells are 
expressed almost exclusively the high molecular weight isoforms (Figure 7). Moreover, when 
we looked at specific genes bound by these TFs we clearly demonstrated that the HIF-
1α/TCF1 complex bound to genes with a gene ontology enriched in neurogenesis and neurons 
maturation processes at 2% oxygen and that TCF4 in normoxia bound to the same genes, 
without exerting any neuronal differentiation effect on GBM cells. Indeed, these genes were 
significantly up-regulated upon Wnt3a treatment in hypoxia while in normoxia their 
expression remained totally comparable to untreated cells. Collectively these data corroborate 
the hypothesis of a TCF4 inhibitory function, finally confirmed by specific gene silencing 
experiments by which we demonstrated that TCF4 inhibition significantly activated the Wnt 
pathway reporter signal and allowed a prompt neuronal differentiation of GBM cells also in 
normoxia (Figure 16).   
What is peculiar in our study is the controversial function of the hypoxic sensor HIF-1α. 
Historically, HIF-1α has been considered as an oncogene, especially in solid tumors which are 
particularly characterized by hypoxic and anoxic areas (80–83) Previous studies from our 
group focused on dissecting the role of hypoxia and HIF-1α in maintaining GBM cells 
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stemness and proliferation (84) demonstrating the relevance of the hypoxic microenvironment 
in supporting the survival of GBM stem cells and promoting their resistance to therapy. 
Physiologically, HIF-1α has a fundamental role in the neuronal differentiation process of the 
developing brain (58,85,86) and, notably, in neuron regeneration and axon reconstruction 
after brain injuries (87). For these reasons, we wondered if the same mechanism could be still 
active in a cancer setting. Our data disclosed that HIF-1α is a crucial player of the neuronal 
differentiation process by strengthening the TCF1-driven Wnt intracellular cascade. 
Moreover, by ChIP-ddPCR experiments we discovered that HIF-1α binds to TCF1, which is 
able to re-direct HIF-1α to TCFs specific sequences and suggesting that HIF-1α functions as a 
helper for TCF1-mediated transcription. Indeed, by functional experiments we demonstrated 
that the fundamental promoter of the GBM cells neuronal differentiation is TCF1 whose 
action is enhanced by HIF-1α in hypoxia and inhibited by TCF4 at 20% oxygen.  
In the last decade, lots of efforts have been made in order to target CSCs and, in particular, 
their resistance to therapies and their ability to recapitulate the entire tumor mass upon 
surgical resection. Thus, pro-differentiating therapy has been proposed as an effective 
approach in attenuating CSC aggressiveness and in reducing chemo- and radioresistance in 
several tumors, comprising GBM (3). Knockdown of CD44 negatively impact on breast 
cancer stem cells, resulting in a loss of stem-like characteristics and an increase in 
susceptibility to chemotherapy and radiation (88) and all-trans-retinoic acid (ATRA) leads to 
complete remission in patients with acute promyelocytic leukemia (APL) by inducing 
terminal cell differentiation by disrupting the promyelocytic leukemia/retinoic acid receptor α 
(PML/RARα) fusion protein that arrests the maturation of myeloid cells at the promyelocytic 
stage (89). In glioma, retinoids (ATRA or 13-CRA) induced astrocytic differentiation of 
GBM cells with a down regulation of the telomerase activity, an increased sensitivity to TXL 
and enhance apoptosis(90). Moreover, in vitro differentiation of stem-like glioma cells with 
ATRA containing medium induces therapy-sensitizing effects, impair the secretion of 
angiogenic cytokines, and disrupts motility (91). 
In our study, we described a mechanism of GBM cell neuronal differentiation induced by Wnt 
pathway activation and characterized the principal mediators of this process by depicting a 
potential therapeutic strategy to be specifically exploited for reducing GBM cells 
aggressiveness. Combining our findings with chemo- and radiotherapy can represent a 
powerful improvement in the management of GBM treatment. 
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CONCLUSIONS 
 
In this study we finely characterized the role of Wnt pathway transcriptional effectors in 
inducing GBM phenotype depending on the microenvironmental conditions. Indeed, we 
definitely uncovered the role of TCF1 in pushing GBM cells to acquire a neuronal phenotype 
through the formation of a transcriptional complex with HIF-1α which is recruited above the 
TCF/LEF sequence to trigger activation of genes implicated in neuronal differentiation 
processes (Figure 25A). Moreover, TCF1 is essential to preserve the ability of the 
transcriptionally active complex in modulating GBM cell phenotype in terms of neuronal 
commitment induction. We demonstrated that the neuronal differentiation process is induced 
at the transcriptional level and impact on the phenotype of GBM cells, strictly depending on 
the microenvironment, and thus confirming the hypothesis that the presence of HIF-1α 
strengthen the action of TCF1 in achieving the neuronal switch of GBM cells. On the other 
hand, high oxygen levels favor the action of an inhibitory isoform of TCF4, TCF4E, whose 
expression is more abundant in GBM cells cultured in normoxia. In this conditions, genes 
involved in the neuronal differentiation processes are inhibited by TCF4 and the Wnt 
pathway-related switch toward neurons that we previously observed at low oxygen levels, is 
not induced (Figure 25B).  
In conclusion, we unveil a tightly regulated mechanism by which the TCF1/HIF-1α 
transcriptional complex is able to induce a reminiscent neuronal differentiation of GSCs, 
which might represent a future potential strategy to therapeutically weaken their 
aggressiveness. 
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

Figure 25. Wnt pathway transcriptional effectors orchestrate the phenotypic balance of GBM cells 
through an oxygen-dependent mechanism. (A) At low oxygen levels, Wnt pathway activation induces the 
formation of a molecular complex formed by TCF1, HIF-1α and β-catenin which triggers the expression of 
genes correlated with neuronal differentiation processes and induces a phenotypic change in GBM cells by 
inducing a switch toward neurons. (B) At high oxygen levels, the formation of the molecular complex is 
impaired upon Wnt pathway activation and, subsequently to HIF-1α , TCF4 can inhibit the activation of genes 
related to neuronal differentiation processes. GBM cells does not encounter a phenotypic switch toward neuron 
and maintain their undifferentiated phenotype. 
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MATERIALS AND METHODS 
 
Neurosurgical sample collection, isolation and gas-controlled expansion of GBM cells  
Written informed consent for the donation of adult tumor brain tissues was obtained from 
patients before tissue acquisition under the auspices of the protocol for the acquisition of 
human brain tissues obtained from the Ethical Committee of the Padova University Hospital. 
All tissues were acquired following the tenets of the Declaration of Helsinki. Patients from 
which we derived GBM primary cultures are listed in supplementary table 1. 
Primary GBM cells were isolated and maintained in culture as described previously (92). 
Briefly, tumor biopsies were subjected to mechanical dissociation and the resulting cell 
suspension was cultured on fibronectin-coated dishes in DMEM/F12 medium supplemented 
with BIT9500 (Stemcell Technologies Inc., Vancouver, Canada), 20ng/ml basic Fibroblast 
Growth Factor (bFGF; Sigma-Aldrich S.r.l., Milan, Italy) and 20ng/ml Epidermal Growth 
Factor (EGF; R&D Systems, Minneapolis, MN). GBM cells were maintained in an 
atmosphere of 2% oxygen, 5% carbon dioxide and balanced nitrogen in a Ruskinn C300 
system for hypoxic cell culture (Ruskinn Technology Ltd, Bridgend, UK). Cells were not 
cultured for more than 8 passages in vitro in order to avoid long term culture related effects. 
To activate Wnt pathway signaling GBM cells were treated with recombinant protein Wnt3a 
(30ng/mL) for a time depending on experimental settings.  
 
Neurosphere forming assay 
Self-renewal capacity of primary GBM cells was assessed as follows: the first day 2 × 
10
5
 cells per well were seeded onto six-well plates with fibronectin-coating. At day one, cells 
were treated with Wnt3a (30ng/ml) under hypoxic or normoxic culture conditions (no treated 
cells were used as control). At day 6, cells were trypsinized and seeded onto uncoated 6-well 
plates at 10
4
 cells per well. After a week, neurospheres were counted and dissociated with 
MgCl 1M (1:1000), DNase (2µL/mL) and trypsine (TrypLE™ Express Enzyme, 
ThermoFischerScientific). After neurosphere disgregation, 104 cells were reseeded onto 
uncoated 6-well plates for secondary neurosphere formation. Others two identical replating 
were carried out. 
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Limiting dilution assay (LDA) 
To assess the GBM cancer initiating cells frequency we set up limiting dilution assays as 
follow: the first day we seeded GBM cells in 6 well coated plates under hypoxic and 
normoxic conditions. Then, we treated cells with Wnt3a (30 ng/mL) for 3 days and, at day 4, 
we replated serial dilutions of cells ranging from 0 to 500 cells per well in 96 well uncoated 
plates. The cells were cultured under low or high oxygen levels for 1 week and then were 
counted the wells in which there was no significant spheres formation. Percentage of wells 
with no spheres were plotted against the number of cells per well seeded into p96 plates. 
 
Western blot 
Equal amounts of proteins (20µg) extracted from primary GBM cells were resolved using a 
SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) Immobilon-p 
membrane (Merk-Millipore, Darmstadt, Germany). Membranes were blocked with I-block™ 
(Thermo Fisher Scientific, Waltham, MA) for at least 1 hour at room temperature and then 
were incubated overnight at 4°C under constant shaking with the primary antibodies listed in 
supplementary table 2. Membranes were next incubated with peroxidase-labeled secondary 
antibodies for 1 hour. All membranes were visualized using ECL Select (GE Healthcare, 
Catania, Italy) and exposed to Amersham Hyperfilm ECL (GE Healthcare).  
 
Immunoprecipitation  
For immunoprecipitation experiments GBM cells were cultured in 10 mm dishes and treated 
with Wnt3a (30ng/ml) after 24 hours in hypoxic or normoxic conditions. No treated cells 
were used as control. After 48 hours from treatment, cells were solubilized in lysis buffer 
(MgCl2 1M, KCl 1M, EDTA 0,5M, TRIS-HCl pH 7.5, Chapso 1%). A small quantity of cell 
lysates prior to binding with antibodies (INPUT) was collected. Then, an equal amount of 
each protein lysate was incubated with polyclonal antibodies, listed in supplementary table 2, 
for 2 hours at 4°C, followed by incubation with 100 µl of protein A/G-Microbeads 
(µMACS
TM
 MultiMACS Protein A/G kit, Miltenyi Biotec) overnight at 4°C. IgG was used as 
negative control. The immune complexes were analyzed by Western blot analyses with 
antibodies listed in supplementary table 2.  
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Immunofluorescence 
GBM cells were cultured on 4-well chamber slides (BD Bioscience, San Jose, CA), treated 
depending on the experimental plan, fixed in cold 4% formaldehyde and stored at +4°C prior 
to analysis. Primary antibody used for the staining was listed in supplementary table 2. After 
incubation, cells were washed and incubated with species-specific secondary antibodies 
conjugated to Alexa dyes (Thermo Fisher Scientific, Waltham, MA). Cells were 
counterstained with DAPI (1:10000; Sigma-Aldrich, Milan, Italy) to evidence cell nuclei and 
measure total cell number. Staining was visualized by epifluorescence with a ViCo 
microscope (Vico, Nikon, Melville, NY). 
  
Chip Sequencing (ChIP-SEQ)  
For ChIP-seq experiments we immunoprecipitated HIF-1α, TCF1 and TCF4 in GBM cells 
treated with Wnt3a (30ng/mL) under hypoxic or normoxic conditions. ChIP-seq experiments 
were performed as previously described(93) with slight modifications. Primary GBM cells 
were crosslinked and washed. Then, cells were lysed in Lysis buffer 1 (50 mM HEPES-KOH, 
pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, 1 × 
protease inhibitors) and, after centrifugation, resuspended in Lysis buffer 2 (10 mM Tris-HCl, 
pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1× protease inhibitors). Cells were 
pelleted and resuspended in Sonication buffer (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 
mM EDTA, 0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.05% N-lauroylsarcosine, 1× protease 
Inhibitors) and sonicated in Bioruptor sonicator. Cell lysates were added to protein G beads 
(Invitrogen 100-04D), previously resuspended in 250 μl of PBS, 0.5% BSA and 5 μg of each 
antibody, and incubated at 4°C overnight.  A small quantity of cell lysates prior to addition to 
the beads was kept as input. Crosslinking was reversed and the DNA of cells was extracted by 
Phenol/Chloroform extraction. For sequence preparation, all samples were prepared with the 
Illumina/Solexa Genomic DNA kit (Illumina- IP-102-1001) according to the manufacturer's 
instructions. 
 
ChIP-SEQ data analysis  
ChIP-Seq datasets were aligned using Bowtie2 (version 2.1.0) (94) to the human genome 
(build hg19) with parameters -k 1 -m 1 -n 2. We used the MACS2 (ver. 2.0.9) (95) to find 
peaks and identifing regions of signal enrichment over the input DNA control, with the 
parameters --no-model --keep-dup=1, 'mfold' was set to 5 and 10000, 'q-value' to 0.05 and 'p-
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value' to 0.0005. The heatmaps of Figure 10A were generated using the 'heatmap.plus' 
function of the 'heatmap.plus.package' of R statistical software. 
 
Gene expression profiling and gene ontology 
The unsupervised hierarchical clustering analysis and the heatmap in Figure 12C was 
generated using the gene list generated intersecting HIF-1α /TCF1 co localizing genes with 
the TCF4 gene list in normoxia and apply it to a cohort of glioma and normal brain samples 
(GSE4290 dataset) (71). Specifically, the clustering analysis was generated with R software  
using Euclidean distance as a distance measure between genes and Ward.D method. 
The level plot in Figure 13A was generated by mediating the expression level of the 20 more 
down-regulated genes in GBM compare to normal brain in each group (normal brain, Glioma 
II, Glioma III and GBM) of considered data set (GSE4290). Specifically, the level plot was 
generated with Morpheus software (https://software.broadinstitute.org/morpheus/). Gene 
ontology analysis were performed by applying specific gene lists to GSEA software 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) with C5 compute overlaps and 
filtering the genesets for FDR q-value below 0.05. 
 
Reverse transcription and real-time PCR 
RNA was extracted from GBM cells using TRIzol reagent (Thermo Fisher Scientific, 
Waltham, MA) according to manufacturer’s instructions and 1-2µg of total RNA reverse-
transcribed using SuperScript™ III First-Strand Synthesis System (Thermo Fisher Scientific, 
Waltham, MA). Quantitative RT-PCR reactions were run in triplicate using Platinum SYBR 
Green Q-PCR Super Mix (Thermo Fisher Scientific, Waltham, MA). Fluorescent emission 
was recorded in real-time (Sequence Detection System 7900HT, Applied Biosystems, Foster 
City, CA). The specificity of primers was confirmed for every PCR run by dissociation curve 
analysis. Primers used are listed in supplementary table 3 and their specificity was confirmed 
with the software Human BLAT Search (http://genome.ucsc.edu). Relative RNA quantities 
were normalized to GUSB according to the ΔΔCt Method. 
 
Transfection of primary GBM cells 
To achieve a suitable gene silencing, GBM cells were transfected with 200 pmol of a small 
interfering RNAs (siRNAs) against TCF7 and TCF7L2 as well as with a non targeting siRNA 
(siNEG) using the Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific, Waltham, 
MA) according to manufacturer’s instructions. Silencer® Select Custom Designed siRNAs 
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have been produced by AMBION (Life Technologies LTD, Waltham, MA) and sequences are 
listed in supplementary table 4. Transfected cells were then cultured for 24-48 hours and the 
analysis of silencing specificity was achieved by WB. 
 
Luciferase reporter assay 
GBM cells were transfected using a protocol for transient transfection of adherent cells using 
TransIT
®
-LT1 Transfection Reagent (Mirus Bio LLC, Madison, WI) with BAT-luciferase 
reporter construct (BAT-lux) (Addgene plasmid # 20890) which consists of seven TCF/LEF-
binding sites upstream of a 0.13-kb fragment containing the minimal promoter–TATA box of 
the gene siamois (96) driving the expression of Firefly luciferase reporter gene. To 
overexpress TCF4 inhibitory isoforms we used the plasmid pcDNA3.1-TCF4E (Addgene 
plasmid # 32738). Luciferase experiments on GBM cells were set as follows: at day 1 cells 
were plated at 2x10
5 
per well, at day 2 cells were transfected with an opportune quantity of 
pcDNA3.1-TCF4E or pcDNA3.1 according to manufacturer's instructions. At day 3, cells 
were transfected with BAT-luciferase reporter construct together with pMAX-GFP plasmid to 
control transfection efficacy and normalize luciferase detection.  At day 4 cells  were treated 
with Wnt3a (30ng/mL) and no treated cells were used as control. At day 5, cells were 
solubilized in passive lysis buffer (PLB, Promega) and luciferase activity was analysed. The 
same experimental set was used for luciferase reporter assays after TCF7 and TCF7L2 
silencing (day2). Values, expressed in relative light units (RLUs), were normalized to the 
values obtained from cells. 
 
Chromatin immunoprecipitation (ChIP) and droplet digital PCR (ddPCR) 
To investigate the molecular binding of transcription factors to specific DNA sequences, we 
set up chromatin immunoprecipitations experiments as follows: first, we transfected GBM 
cells cultured under hypoxic or normoxic conditions with the 7X TCF/LEF binding site based 
BAT-lux reporter. The day after transfection, cells were treated with Wnt3a to activate the 
signaling pathway (no treated cells are used for negative control) and, in another experimental 
setting, silenced for TCF1 (siNEG was used as negative control). The day after, cells were 
fixed with formaldehyde, lysated in an appropriate lysis buffer and sonicated in a water bath 
sonicator. Then, immunoprecipitation was performed using HIF-1α antibody (IgG antibody 
will be used as isotype control). Purification of plasmid-DNA was performed by 
phenol/chloroform extraction. We also obtained an INPUT sample for subsequent data 
normalization. To analyze the DNA sequences bound to HIF-1α we set up Digital-PCR 
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(ddPCR) experiments using EvaGreen Digital PCR Supermix (Bio-Rad) and a pair of primers 
(listed in supplementary table 3) able to amplify the 7xTCF binding sites DNA sequence. 
Then, each sample was emulsionated and the obtained droplets were processed in a standard 
thermocycler. After the amplification, the droplets generated for each sample (INPUT, IgG as 
negative control, ChIP samples) were processed in the QX200 Droplet Digital PCR 
(ddPCR™) System. DNA quantity of each ChIP sample was measured as DNA copies/µL 
and was normalized on each experimental INPUT, obtaining the enrichment over input ratio 
plotted on the bar graphs.  
 
Immunohistochemistry 
TCF1, HIF-1 and β-III-tubulin immunohistochemistry was conducted on 5μm sections of 
paraffin embedded GBM specimens with standard procedures. Briefly, sections were re-
hydrated and then antigen retrieval was performed by incubation with citrate buffer 0.01M 
pH6 at 95°C. After saturation with the more appropriate normal serum, slides were incubated 
with the primary antibody listed in supplementary table 2. After incubation, sections were 
washed and incubated with species-specific biotin-conjugated secondary antibodies (Vector 
Laboratories Inc. Burlingame, CA). TCF1, HIF-1and β-III-tubulin expression was revealed 
by using the Dako Liquid DAB
+
 Substrate Chromogen System (Dako, Glostrup, Denmark) 
according to manufacturer’s guidelines. Tissues were counterstained with Meyer’s 
Hematoxylin and images acquired with a Zeiss Imager M1 microscope (Carl Zeiss, 
Oberkochen, Germany). The specificity of each staining procedure was confirmed by 
replacing the primary antibodies with an Isotype control.  
The expression level of TCF1 and HIF-1was scored using a combined method accounting 
for both the staining intensity and the percentage of positive stained cells. The resulting 
combined score was calculated as the multiplication of the score accounting for the 
percentage of TCF1
+
 cell nuclei or HIF-1 cell nuclei (0-6) and the intensity score (0-3). 
TCF1, HIF-1 and β-III-tubulin stained slides were independently evaluated by two different 
pathologists. 
 
Statistical analyses 
Graphs and associated statistical analyses were generated using Graph Pad Prism 6.07 
(GraphPad, La Jolla, CA). All data in bar graphs are presented as mean ± standard error of the 
mean (S.E.M.). Statistical significance was measured by one-way ANOVA with Newman–
Keuls multiple comparison post test (for more than two comparisons) and paired t-test 
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(comparison of two groups); *p<0.05, **p<0.01, ***p<0.001. For all graphs, asterisks over 
brackets indicate a significant difference with another variable as indicated and asterisks over 
bars indicate a significant difference with the control group. Integration of IHC data has been 
obtained by applying Principal Component Analysis to IHC scores.  
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SUPPLEMENTARY TABLES 
Supplementary table 1: GBM patient-derived cells used in this study 
Patient Diagnosis Age Sex 
HuTuP01 Glioblastoma 64 Male 
HuTuP10 Glioblastoma 75 Female 
HuTuP13 Glioblastoma 67 Male 
HuTuP36 Glioblastoma  49 Female 
HuTuP43 Glioblastoma 59 Male 
HuTuP47 Glioblastoma 81 Female 
HuTuP53 Glioblastoma 70 Male 
HutuP82 Glioblastoma 50 Male 
HuTu83 Glioblastoma 55 Male 
HuTu174 Glioblastoma 69 Male 
HuTu175 Glioblastoma 57 Female 
HuTu187 Glioblastoma 56 Male 
HuTu197 Glioblastoma 48 Male 
Brain tumours were acquired directly from surgery, dissociated and cells were expanded in 
culture. First neuropathological review of the tumour tissue was followed by a second 
independent review. Patient ages listed in years (y). 
 
Supplementary table 2: Antibodies used in this study 
Antibody MW (kDa) Manufacturer Host Application 
TCF1 48,50 Cell Signaling Rabbit WB 
TCF1 / Sigma-Aldrich Mouse IHC/IF 
TCF4 58,79 Cell Signaling Rabbit WB 
TCF4 / Sigma-Aldrich Mouse IHC/IF 
HIF-1α 120 BD Biosciences Mouse WB 
HIF-1α / Abcam Rabbit IP/ChIP 
HIF-1α / Sigma-Aldrich Rabbit IHC 
β-actin 45 Sigma-Aldrich Mouse WB 
β-catenin 85 Abcam Rabbit IP/WB 
Nestin / Millipore Rabbit IF 
β-III tubulin / Covance Mouse IF/IHC 
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Supplementary table 3: Sequence of primers used in this study 
Gene Sequence (5’-3’) Amplicon (bp) 
BAT-lux plasmid forward CGCGGGAATTCGATTAAGGAC 
291 
BAT-lux plasmid  reverse AACAGGGGACAAAGGGTGTG 
CHRM3 forward  GCCGGGATCATCATGACCGT 
175 
CHRM3 reverse TGCATCGGAGGGGCTGTGTAT 
TCF7 forward CCTAGCAAGGAGGAGCGAGA 
143 
TCF7 reverse CCGGTTGGCAAACCAGTTGTAG 
TCF7L2 forward 
TCF7L2 reverse 
TTTAAGGGGCCACCGTATCC 
TGCCGGACTGAAAATGGAG 
119 
CMIP forward GGGGTCTCGCACAGGTTCAG 
236 
CMIP reverse GGGGTCTCGCACAGGTTCAG 
LR1PB forward AGATGCTGTGGCCAAACGGT 
160 
LR1PB reverse TGCGACAGTCCGAAAGGGTG 
β-glucuronidase (GUSB) forward GAAAATACGTGGTTGGAGAGCTCATT 
101 
β-glucuronidase (GUSB) reverse CCGAGTGAAGATCCCCTTTTTA 
 
Supplementary table 4: Sequence of siRNA used in this study 
Gene Sequence Manufacturer 
TCF7 5’AUGCUAGGUUCUGGUGUACtt3’ Ambion 
TCF7L2 5’CACGCCUCUUAUCACGUACtt3’ Ambion 
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ABBREVIATIONS USED IN THE TEXT 
 
ATRA  All-trans-retinoic acid 
bFGF  Basic fibroblast growth factor 
BMP  Bone morphogenetic protein 
CAIX  Carbonic anydrase 9 
ChIP  Chromatin immunoprecipitation 
DAPI  4',6-diamidin-2-fenilindolo 
ddPCR Droplet digital polymerase chain reaction 
DMEM Dulbecco’s modified eagle medium 
ECL  Enhanced chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid 
EGTA  Egtazic acid 
EGF  Endothelial growth factor 
FDR  False discovery rate 
GBM  Glioblastoma multiforme 
GFAP  Glial fibrillary acidic protein  
GO  Gene ontology 
GSC  Glioma stem cell 
GSEA  Gene set enrichment 
GSK3  Glycogen synthase kinase3 
HIF  Hypoxia-inducible factor 
HMG  High-mobility Group  
HRE  Hypoxia-response element 
IF  Immunofluorescence 
IHC  Immunohistochemistry 
IP  Immunoprecipitation 
LDA  Limiting dilution assay 
LEF  Lymphoid enhancer factor 
MW  Molecular weight 
NFAT  Nuclear factor of activated T-cells 
NSC  Neural stem cell 
ODDD Oxygen-dependent degradation domain 
PCA  Principal component analysis 
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PCR  Polymerase chain reaction  
PHD  Prolyl hydroxylase domain 
PVDF  Polyvinylidene Difluoride 
RLU  Relative light unit 
RTK  Receptor tyrosine kinase 
SDS  Sodium dodecyl sulfate 
SGZ  Subgranular zone 
SP  Side population 
SVZ  Subventricular zone 
TCF1  T-cell factor 1 
TCF4  T-cell factor 4 
TDEC  Tumor-derived endothelial cells 
TF  Transcription factor 
TGF-β  Transforming growth factor beta 
TMZ  Temozolomide 
TSS  Transcriptional starting site 
TXL  Taxol 
VEGF  Vascular endothelial growth factor 
VHL  von Hippel-Lindau disease tumor suppressor 
WB  Western blot 
WNT  Wingless-related integration site 
 
